Busca un médico

Alton O. Sartor, M.D.

  1. Oncologist
Solicite una Consulta

Publicaciones

  1. Muniz M, Sartor O, Orme JJ, Koch RM, Rosenow HR, Mahmoud AM, Andrews JR, Kase AM, Riaz IB, Belge Bilgin G, Thorpe MP, Kendi AT, Johnson GB, Ravi P, Kwon ED, Childs DS. Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer and Liver Metastasis Receiving [(177)Lu]Lu-PSMA-617. J Nucl Med. 2024 Dec 3; 65 (12):1932-1938 Epub 2024 Dec 03
    View PubMed
  2. Esfahani SA, Morris MJ, Sartor O, Frydenberg M, Fanti S, Calais J, Vapiwala N. Standardized template for clinical reporting of PSMA PET/CT scans. Eur J Nucl Med Mol Imaging. 2024 Dec; 52 (1):335-341 Epub 2024 Aug 15
    View PubMed
  3. Calais J, Morris MJ, Kendi AT, Kalebasty AR, Tutrone R, Anderson MJ, Sartor O. Best Patient Care Practices for Administering PSMA-Targeted Radiopharmaceutical Therapy. J Nucl Med. 2024 Nov 1; 65 (11):1666-1671 Epub 2024 Nov 01
    View PubMed
  4. Herrmann K, Gafita A, de Bono JS, Sartor O, Chi KN, Krause BJ, Rahbar K, Tagawa ST, Czernin J, El-Haddad G, Wong CC, Zhang Z, Wilke C, Mirante O, Morris MJ, Fizazi K. Multivariable models of outcomes with [(177)Lu]Lu-PSMA-617: analysis of the phase 3 VISION trial. EClinicalMedicine. 2024 Nov; 77:102862 Epub 2024 Oct 04
    View PubMed
  5. Murthy V, Voter AF, Nguyen K, Allen-Auerbach M, Chen L, Caputo S, Ledet E, Akerele A, Moradi Tuchayi A, Lawhn-Heath C, Wang T, Carducci MA, Pomper MG, Paller CJ, Czernin J, Solnes LB, Hope TA, Sartor O, Calais J, Gafita A. Efficacy and Toxicity of [(177)Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data. J Nucl Med. 2024 Nov 1; 65 (11):1740-1744 Epub 2024 Nov 01
    View PubMed
  6. Sollini M, Calais J, Chiti A, Emmett L, Fanti S, Fendler W, Herrmann K, Hope TA, Sartor O, Shuch B, Tagawa S, Hofman MS. Novel Radiopharmaceuticals and Future of Theranostics in Genitourinary Cancers. Eur Urol. 2024 Oct 19 [Epub ahead of print]
    View PubMed
  7. McManus HD, Dorff T, Morgans AK, Sartor O, Shore N, Armstrong AJ. Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey. Prostate Cancer Prostatic Dis. 2024 Oct 17 [Epub ahead of print]
    View PubMed
  8. Morris MJ, de Bono J, Nagarajah J, Sartor O, Wei XX, Nordquist LT, Koshkin VS, Chi KN, Krause BJ, Herrmann K, Rahbar K, Vickers A, Mirante O, Ghouse R, Fizazi K, Tagawa ST. Correlation analyses of radiographic progression-free survival with clinical and health-related quality of life outcomes in metastatic castration-resistant prostate cancer: Analysis of the phase 3 VISION trial. Cancer. 2024 Oct 15; 130 (20):3426-3435 Epub 2024 June 21
    View PubMed
  9. Gillessen S, Turco F, Davis ID, Efstathiou JA, Fizazi K, James ND, Shore N, Small E, Smith M, Sweeney CJ, Tombal B, Zilli T, Agarwal N, Antonarakis ES, Aparicio A, Armstrong AJ, Bastos DA, Attard G, Axcrona K, Ayadi M, Beltran H, Bjartell A, Blanchard P, Bourlon MT, Briganti A, Bulbul M, Buttigliero C, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Clarke CS, Clarke N, de Bono JS, De Santis M, Duran I, Efstathiou E, Ekeke ON, El Nahas TIH, Emmett L, Fanti S, Fatiregun OA, Feng FY, Fong PCC, Fonteyne V, Fossati N, George DJ, Gleave ME, Gravis G, Halabi S, Heinrich D, Herrmann K, Hofman MS, Hope TA, Horvath LG, Hussain MHA, Jereczek-Fossa BA, Jones RJ, Joshua AM, Kanesvaran R, Keizman D, Khauli RB, Kramer G, Loeb S, Mahal BA, Maluf FC, Mateo J, Matheson D, Matikainen MP, McDermott R, McKay RR, Mehra N, Merseburger AS, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Mutambirwa SBA, Nguyen PL, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Renard-Penna R, Ryan CJ, Saad F, Sade JP, Sandhu S, Sartor OA, Schaeffer E, Scher HI, Sharifi N, Skoneczna IA, Soule HR, Spratt DE, Srinivas S, Sternberg CN, Suzuki H, Taplin ME, Thellenberg-Karlsson C, Tilki D, Turkeri LN, Uemura H, Urun Y, Vale CL, Vapiwala N, Walz J, Yamoah K, Ye D, Yu EY, Zapatero A, Omlin A. Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC). Eur Urol. 2024 Oct 10 [Epub ahead of print]
    View PubMed
  10. Clarke NW, Armstrong AJ, Oya M, Shore N, Procopio G, Daniel Guedes J, Arslan C, Mehra N, Parnis F, Brown E, Schlurmann F, Young Joung J, Sugimoto M, Sartor O, Poehlein C, McGuinness D, Degboe A, Saad F. Efficacy and Safety of Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone in the First-line Treatment of Patients with Asymptomatic/Mildly Symptomatic and Symptomatic Metastatic Castration-resistant Prostate Cancer: Analyses from the Phase 3 PROpel Trial. Eur Urol Oncol. 2024 Oct 8 Epub 2024 Oct 08
    View PubMed
  11. Ross AE, Zhang J, Huang HC, Yamashita R, Keim-Malpass J, Simko JP, DeVries S, Morgan TM, Souhami L, Dobelbower MC, McGinnis LS, Jones CU, Dess RT, Zeitzer KL, Choi K, Hartford AC, Michalski JM, Raben A, Gomella LG, Sartor AO, Rosenthal SA, Sandler HM, Spratt DE, Pugh SL, Mohamad O, Esteva A, Chen E, Schaeffer EM, Tran PT, Feng FY. External Validation of a Digital Pathology-based Multimodal Artificial Intelligence Architecture in the NRG/RTOG 9902 Phase 3 Trial. Eur Urol Oncol. 2024 Oct; 7(5):1024-1033. Epub 2024 Feb 01.
    View PubMed
  12. Belge Bilgin G, Burkett BJ, Bilgin C, Orme JJ, Childs DS, Rincon MM, Abdelrazek AS, Johnson DR, Johnson GB, Kwon ED, Sartor O, Kendi AT. Neurologic Symptoms After (177)Lu-Prostate-Specific-Membrane Antigen-617 Therapy: A Single-Center Experience. J Nucl Med. 2024 Sep 3; 65 (9):1402-1408 Epub 2024 Sept 03
    View PubMed
  13. Chauhan PS, Alahi I, Sinha S, Ledet EM, Mueller R, Linford J, Shiang AL, Webster J, Greiner L, Yang B, Ni G, Dang HX, Saha D, Babbra RK, Feng W, Harris PK, Qaium F, Duose DY, Sanchez-Espitia A, Sherry AD, Jaeger EB, Miller PJ, Caputo SA, Orme JJ, Lucien F, Park SS, Tang C, Pachynski RK, Sartor O, Maher CA, Chaudhuri AA. Genomic and epigenomic analysis of plasma cell-free DNA identifies stemness features associated with worse survival in lethal prostate cancer. Clin Cancer Res. 2024 Aug 23. [Epub ahead of print]
    View PubMed
  14. Orme JJ, Taza F, De Sarkar N, Tewari AK, Arsalan Naqvi S, Riaz IB, Childs DS, Omar N, Adra N, Ashkar R, Cheng HH, Schweizer MT, Sokolova AO, Agarwal N, Barata P, Sartor O, Bastos D, Smaletz O, Berchuck JE, McClure H, Taplin ME, Aggarwal R, Sternberg CN, Vlachostergios PJ, Alva AS, Mehra N, Nelson PS, Hwang J, Dehm SM, Shi Q, Fleischmann Z, Sokol ES, Elliott A, Huang H, Bryce A, Marshall CH, Antonarakis ES. Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer. Eur Urol Oncol. 2024 Aug; 7 (4):877-887 Epub 2023 Dec 09
    View PubMed
  15. Kuo PH, Morris MJ, Hesterman J, Kendi AT, Rahbar K, Wei XX, Fang B, Adra N, Garje R, Michalski JM, Chi K, de Bono J, Fizazi K, Krause B, Sartor O, Tagawa ST, Ghebremariam S, Brackman M, Wong CC, Catafau AM, Benson T, Armstrong AJ, Herrmann K. Quantitative (68)Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following (177)Lu-PSMA-617 (VISION Trial). Radiology. 2024 Aug; 312 (2):e233460
    View PubMed
  16. Sartor O, Karrison TG, Sandler HM, Gomella LG, Amin M, Purdy J, Michalski JM, Garzotto MG, Pervez N, Balogh AG, Rodrigues GB, Souhami L, Neil Reaume M, Williams SG, Hannan R, Jones CU, Horwitz EM, Rodgers JP, Feng FY, Rosenthal SA. Corrigendum to "Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostat Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial" [Eur. Eurol. 84(2) (2023) 156-163]. Eur Urol. 2024 Jun 18 Epub 2024 June 18
    View PubMed
  17. Muniz M, Loprinzi CL, Orme JJ, Koch RM, Mahmoud AM, Kase AM, Riaz IB, Andrews JR, Thorpe MP, Johnson GB, Kendi AT, Kwon ED, Nauseef JT, Morgans AK, Sartor O, Childs DS. Salivary toxicity from PSMA-targeted radiopharmaceuticals: What we have learned and where we are going. Cancer Treat Rev. 2024 Jun; 127:102748 Epub 2024 Apr 30
    View PubMed
  18. Miller CD, Lozada JR, Zorko NA, Elliott A, Makovec A, Radovich M, Heath EI, Agarwal N, Mckay RR, Garje R, Bastos BR, Hoon DSB, Orme JJ, Sartor O, VanderWalde A, Nabhan C, Sledge G, Shenderov E, Dehm SM, Lou E, Miller JS, Hwang JH, Antonarakis ES. Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies. Cancer Res Commun. 2024 May 30; 4(5):1369-1379.
    View PubMed
  19. Muniz M, Childs DS, Orme JJ, Johnson GB, Sartor O. Reversibility of Bicalutamide PSMA PET-Positive Gynecomastia With Androgen Deprivation Therapy. Clin Nucl Med. 2024 Apr 01; 49(4):e164-e165. Epub 2024 Feb 06.
    View PubMed
  20. Chi KN, Armstrong AJ, Krause BJ, Herrmann K, Rahbar K, de Bono JS, Adra N, Garje R, Michalski JM, Kempel MM, Fizazi K, Morris MJ, Sartor O, Brackman M, DeSilvio M, Wilke C, Holder G, Tagawa ST. Safety Analyses of the Phase 3 VISION Trial of [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2024 Apr; 85(4):382-391. Epub 2024 Jan 06.
    View PubMed
  21. Xie W, Ravi P, Buyse M, Halabi S, Kantoff P, Sartor O, Soule H, Clarke N, Dignam J, James N, Fizazi K, Gillessen S, Mottet N, Murphy L, Parulekar W, Sandler H, Tombal B, Williams S, Sweeney CJ. Validation of metastasis-free survival as a surrogate endpoint for overall survival in localized prostate cancer in the era of docetaxel for castration-resistant prostate cancer. Ann Oncol. 2024 Mar; 35(3):285-292. Epub 2023 Dec 05.
    View PubMed
  22. Tagawa ST, Thomas C, Sartor AO, Sun M, Stangl-Kremser J, Bissassar M, Vallabhajosula S, Huicochea Castellanos S, Nauseef JT, Sternberg CN, Molina A, Ballman K, Nanus DM, Osborne JR, Bander NH. Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225Ac-J591. J Clin Oncol. 2024 Mar 01; 42(7):842-851. Epub 2023 Nov 03.
    View PubMed
  23. Higano CS, Dizdarevic S, Logue J, Richardson T, George S, de Jong I, Tomaszewski JJ, Saad F, Miller K, Meltzer J, Sandstrom P, Verholen F, Tombal B, Sartor O. Safety and effectiveness of the radium-223-taxane treatment sequence in patients with metastatic castration-resistant prostate cancer in a global observational study (REASSURE). Cancer. 2024 Feb 10 [Epub ahead of print]
    View PubMed
  24. Carrot A, Oudard S, Colomban O, Fizazi K, Maillet D, Sartor O, Freyer G, You B. Prognostic Value of the Modeled Prostate-Specific Antigen KELIM Confirmation in Metastatic Castration-Resistant Prostate Cancer Treated With Taxanes in FIRSTANA. JCO Clin Cancer Inform. 2024 Feb; 8:e2300208
    View PubMed
  25. Sartor O, Fizazi K, Herrmann K, Morris MJ. Design Considerations in the PSMAfore Trial. J Nucl Med 2024 Feb 1; 65 (2):226-227 Epub 2024 Feb 01
    View PubMed
  26. Oprea-Lager DE, MacLennan S, Bjartell A, Briganti A, Burger IA, de Jong I, De Santis M, Eberlein U, Emmett L, Fizazi K, Gillessen S, Herrmann K, Heskamp S, Iagaru A, Jereczek-Fossa BA, Kunikowska J, Lam M, Nanni C, O'Sullivan JM, Panebianco V, Sala E, Sathekge M, Sosnowski R, Tilki D, Tombal B, Treglia G, Tunariu N, Walz J, Yakar D, Dierckx R, Sartor O, Fanti S. European Association of Nuclear Medicine Focus 5: Consensus on Molecular Imaging and Theranostics in Prostate Cancer. Eur Urol. 2024 Jan; 85 (1):49-60 Epub 2023 Sept 22
    View PubMed
  27. Belge Bilgin G, Bilgin C, Childs DS, Orme JJ, Burkett BJ, Packard AT, Johnson DR, Thorpe MP, Riaz IB, Halfdanarson TR, Johnson GB, Sartor O, Kendi AT. Performance of ChatGPT-4 and Bard chatbots in responding to common patient questions on prostate cancer (177)Lu-PSMA-617 therapy. Front Oncol. 2024; 14:1386718 Epub 2024 July 12
    View PubMed
  28. Belge Bilgin G, Bilgin C, Burkett BJ, Orme JJ, Childs DS, Thorpe MP, Halfdanarson TR, Johnson GB, Kendi AT, Sartor O. Theranostics and artificial intelligence: new frontiers in personalized medicine. Theranostics. 2024; 14(6):2367-2378. Epub 2024 Mar 25.
    View PubMed
  29. Belge Bilgin G, Navin PJ, Johnson DR, Sartor O, Kendi AT. Acute pancreatitis and biliary obstruction from metastatic lymph node compression during [(177)Lu] Lu-PSMA-617 therapy: a case report. Front Oncol. 2024; 14:1442293 Epub 2024 Oct 07
    View PubMed
  30. Rahbar K, Essler M, Eiber M, la Fougere C, Prasad V, Fendler WP, Rassek P, Hasa E, Dittmann H, Bundschuh RA, Pabst KM, Kurtinecz M, Schmall A, Verholen F, Sartor O. (177)Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior (223)Ra (RALU Study). J Nucl Med. 2023 Dec 1; 64 (12):1925-1931 Epub 2023 Dec 01
    View PubMed
  31. Sartor O, Ledet E, Huang M, Schwartz J, Lieberman A, Lewis B, Layton J, Barata P, Jang A, Hawkins M, Pocha O, Lanka S, Harris K. Prediction of Resistance to (177)Lu-PSMA Therapy by Assessment of Baseline Circulating Tumor DNA Biomarkers. J Nucl Med. 2023 Nov; 64 (11):1721-1725 Epub 2023 Sept 28
    View PubMed
  32. Saad F, Clarke NW, Oya M, Shore N, Procopio G, Guedes JD, Arslan C, Mehra N, Parnis F, Brown E, Schlurmann F, Joung JY, Sugimoto M, Sartor O, Liu YZ, Poehlein C, Barker L, Del Rosario PM, Armstrong AJ. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023 Oct; 24 (10):1094-1108 Epub 2023 Sept 12
    View PubMed
  33. Hope TA, Antonarakis ES, Bodei L, Calais J, Iravani A, Jacene H, Koo PJ, Morgans AK, Osborne JR, Tagawa ST, Taplin ME, Sartor O, Morris MJ. SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-PSMA-617 Radionuclide Therapy. J Nucl Med. 2023 Sep; 64(9):1417-1423. Epub 2023 Jun 08.
    View PubMed
  34. Lazzari L, Ledet E, Hawkins M, Sartor O. Severe hypercalcaemia in metastatic prostate cancer with biallelic BRCA2 mutations and lytic bone lesions. BMJ Case Rep. 2023 Aug 10; 16 (8)
    View PubMed
  35. Caputo SA, Blair G, Hawkins M, Harris K, Sartor O. Unusual Case of Missed Penile Metastases on 68 Ga-PSMA PET/CT. Clin Nucl Med. 2023 Aug 1; 48 (8):710-711 Epub 2023 June 06
    View PubMed
  36. Jang A, Lanka SM, Huang M, Casado CV, Caputo SA, Sweeney PL, Gupta K, Pocha O, Habibian N, Hawkins ME, Lieberman AD, Schwartz J, Jaeger EB, Miller PJ, Layton JL, Barata PC, Lewis BE, Ledet EM, Sartor O. Comparison of circulating tumor DNA between African American and Caucasian patients with metastatic castrate-resistant prostate cancer post-abiraterone and/or enzalutamide. Prostate. 2023 Aug; 83 (11):1028-1034 Epub 2023 Apr 27
    View PubMed
  37. Sartor O, Karrison TG, Sandler HM, Gomella LG, Amin MB, Purdy J, Michalski JM, Garzotto MG, Pervez N, Balogh AG, Rodrigues GB, Souhami L, Reaume MN, Williams SG, Hannan R, Jones CU, Horwitz EM, Rodgers JP, Feng FY, Rosenthal SA. Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial. Eur Urol. 2023 Aug; 84 (2):156-163 Epub 2023 May 12
    View PubMed
  38. Jang A, Kendi AT, Johnson GB, Halfdanarson TR, Sartor O. Targeted Alpha-Particle Therapy: A Review of Current Trials. Int J Mol Sci. 2023 Jul 19; 24(14).
    View PubMed
  39. Jang A, Lanka SM, Jaeger EB, Lieberman A, Huang M, Sartor AO, Mendiratta P, Brown JR, Garcia JA, Farmer T, Sudhaman S, Mahmood T, Pajak N, Calhoun M, Dutta P, ElNaggar A, Liu MC, Barata PC. Longitudinal Monitoring of Circulating Tumor DNA to Assess the Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Genitourinary Malignancies. JCO Precis Oncol. 2023 Jul; 7:e2300131
    View PubMed
  40. Caputo SA, Hawkins M, Jaeger EB, Fleming W, Casado C, Manogue C, Huang M, Lieberman A, Light M, Sussman IP, Miller P, Barata PC, Lewis BE, Layton JL, Ledet EM, Antonarakis ES, Sartor O. Clinical and molecular determinants of PSA response to bipolar androgen therapy in prostate cancer. Prostate. 2023 Jun; 83 (9):879-885 Epub 2023 Apr 04
    View PubMed
  41. Higano CS, George DJ, Shore ND, Sartor O, Miller K, Conti PS, Sternberg CN, Saad F, Sade JP, Bellmunt J, Smith MR, Chandrawansa K, Sandstrom P, Verholen F, Tombal B. Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancer. EClinicalMedicine. 2023 Jun; 60:101993 Epub 2023 May 18
    View PubMed
  42. Fizazi K, Herrmann K, Krause BJ, Rahbar K, Chi KN, Morris MJ, Sartor O, Tagawa ST, Kendi AT, Vogelzang N, Calais J, Nagarajah J, Wei XX, Koshkin VS, Beauregard JM, Chang B, Ghouse R, DeSilvio M, Messmann RA, de Bono J. Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol.. 2023; 24(6):597-610.
    View PubMed
  43. Pomykala KL, Hadaschik BA, Sartor O, Gillessen S, Sweeney CJ, Maughan T, Hofman MS, Herrmann K. Next generation radiotheranostics promoting precision medicine. Ann Oncol. 2023 Jun; 34 (6):507-519 Epub 2023 Mar 15
    View PubMed
  44. Jang A, Caputo SA, Hawkins ME, Talbert JE, Sartor O. PSMA PET/CT Detection of Chondromyxoid Fibroma. Clin Nucl Med. 2023 Jun 1; 48 (6):545-546 Epub 2023 Apr 05
    View PubMed
  45. Ramnaraign B, Sartor O. PSMA-Targeted Radiopharmaceuticals in Prostate Cancer: Current Data and New Trials. Oncologist. 2023 May 8; 28 (5):392-401
    View PubMed
  46. Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, Mottet N, Shore N, Small E, Smith M, Sweeney CJ, Tombal B, Antonarakis ES, Aparicio AM, Armstrong AJ, Attard G, Beer TM, Beltran H, Bjartell A, Blanchard P, Briganti A, Bristow RG, Bulbul M, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Chowdhury S, Clarke CS, Clarke N, Daugaard G, De Santis M, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ekeke ON, Evans CP, Fanti S, Feng FY, Fonteyne V, Fossati N, Frydenberg M, George D, Gleave M, Gravis G, Halabi S, Heinrich D, Herrmann K, Higano C, Hofman MS, Horvath LG, Hussain M, Jereczek-Fossa BA, Jones R, Kanesvaran R, Kellokumpu-Lehtinen PL, Khauli RB, Klotz L, Kramer G, Leibowitz R, Logothetis C, Mahal B, Maluf F, Mateo J, Matheson D, Mehra N, Merseburger A, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Nguyen PL, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Pezaro CJ, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin MA, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Sharifi N, Skoneczna I, Soule H, Spratt DE, Srinivas S, Sternberg CN, Steuber T, Suzuki H, Sydes MR, Taplin ME, Tilki D, Turkeri L, Turco F, Uemura H, Uemura H, Urun Y, Vale CL, van Oort I, Vapiwala N, Walz J, Yamoah K, Ye D, Yu EY, Zapatero A, Zilli T, Omlin A. Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. Eur J Cancer. 2023 May; 185:178-215 Epub 2023 Mar 03
    View PubMed
  47. Jang A, Jaeger EB, Ledet EM, Xie J, Lewis BE, Layton JL, Sartor O, Barata PC, Trevino CR. Clinical and Genetic Analysis of Metastatic Prostate Cancer to the Central Nervous System: A Single-Institution Retrospective Experience. Clin Genitourin Cancer. 2023 Apr; 21 (2):e9-e18 Epub 2022 Oct 20
    View PubMed
  48. Rahbar K, Essler M, Pabst KM, Eiber M, Fougere C, Prasad V, Rassek P, Hasa E, Dittmann H, Bundschuh RA, Fendler WP, Kurtinecz M, Schmall A, Verholen F, Sartor O. Safety and Survival Outcomes of (177)Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior (223)Ra treatment: The RALU Study. J Nucl Med. 2023 Apr; 64 (4):574-578 Epub 2022 Oct 27
    View PubMed
  49. Hawkins CM, Barata PC, Cotogno P, Davis G, Jaeger E, Ledet E, Miller P, Lewis B, Sartor O, Layton J. Black Patients with Metastatic Castrate-Resistant Prostate Cancer Have a Shorter Time Interval Between PSA and Clinical Progression on Novel Hormonal Therapies plus Avelumab. Oncologist. 2023 Mar 17; 28 (3):276-e158
    View PubMed
  50. Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, Mottet N, Shore N, Small E, Smith M, Sweeney C, Tombal B, Antonarakis ES, Aparicio AM, Armstrong AJ, Attard G, Beer TM, Beltran H, Bjartell A, Blanchard P, Briganti A, Bristow RG, Bulbul M, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Chowdhury S, Clarke CS, Clarke N, Daugaard G, De Santis M, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ngozi Ekeke O, Evans CP, Fanti S, Feng FY, Fonteyne V, Fossati N, Frydenberg M, George D, Gleave M, Gravis G, Halabi S, Heinrich D, Herrmann K, Higano C, Hofman MS, Horvath LG, Hussain M, Jereczek-Fossa BA, Jones R, Kanesvaran R, Kellokumpu-Lehtinen PL, Khauli RB, Klotz L, Kramer G, Leibowitz R, Logothetis CJ, Mahal BA, Maluf F, Mateo J, Matheson D, Mehra N, Merseburger A, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Nguyen PL, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Pezaro C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin MA, Ryan CJ, Saad F, Pablo Sade J, Sartor OA, Scher HI, Sharifi N, Skoneczna I, Soule H, Spratt DE, Srinivas S, Sternberg CN, Steuber T, Suzuki H, Sydes MR, Taplin ME, Tilki D, Turkeri L, Turco F, Uemura H, Uemura H, Urun Y, Vale CL, van Oort I, Vapiwala N, Walz J, Yamoah K, Ye D, Yu EY, Zapatero A, Zilli T, Omlin A. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. Eur Urol 2023 Mar; 83 (3):267-293 Epub 2022 Dec 06
    View PubMed
  51. Hawkey NM, Broderick A, George DJ, Sartor O, Armstrong AJ. The Value of Phenotypic Precision Medicine in Prostate Cancer. Oncologist. 2023 Feb 8; 28 (2):93-104
    View PubMed
  52. Su CT, Nizialek E, Berchuck JE, Vlachostergios PJ, Ashkar R, Sokolova A, Barata PC, Aggarwal RR, McKay RR, Agarwal N, McClure HM, Nafissi N, Bryce AH, Sartor O, Sayegh N, Cheng HH, Adra N, Sternberg CN, Taplin ME, Cieslik M, Alva AS, Antonarakis ES. Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer. Prostate. 2023 Feb; 83(3):227-236. Epub 2022 Nov 16.
    View PubMed
  53. Caputo SA, Jang A, Talbert J, Saba NS, Sartor O. Prostate-Specific Membrane Antigen PET Positivity in a Lung Mass: Diagnosis of Diffuse Large B-Cell Lymphoma. Clin Nucl Med. 2023 Feb 1; 48 (2):190-191
    View PubMed
  54. Quinn Z, Leiby B, Sonpavde G, Choudhury AD, Sweeney C, Einstein D, Szmulewitz R, Sartor O, Knudsen K, Yang ES, Kelly WK. Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer. Clin Cancer Res. 2023 Jan 4; 29 (1):50-59
    View PubMed
  55. Jang A, Kendi AT, Sartor O. Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials. Ther Adv Med Oncol. 2023; 15:17588359231157632 Epub 2023 Mar 04
    View PubMed
  56. Manogue C, Fleming W, Ledet E, Jaeger E, Layton J, Barata P, Lewis B, Sartor O. Continuous IV Infusion of 5-Flourouracil in Heavily Pretreated Metastatic Castrate-Resistant Prostate Cancer. Clin Genitourin Cancer. 2022 Dec; 20 (6):586-590 Epub 2022 June 26
    View PubMed
  57. Sartor O. Outcome of Patients with PSMA PET/CT Screening Failure by VISION Criteria and Treated with (177)Lu-PSMA: A Multicenter Retrospective Analysis. J Nucl Med. 2022 Oct; 63 (10):1482-1483 Epub 2022 May 26
    View PubMed
  58. Zimmerman R, Bilen MA, Heath EI, Nandagopal L, Swami U, Kessel A, Jaeger E, Wesolowski S, Hernanadez EJ, Chipman J, Mack A, Ravindranathan D, Maughan BL, Nussenzveig R, Yandell M, Kohli M, Lilly MB, Sartor AO, Agarwal N, Barata PC. Comprehensive Genomic Profiling of Cell-Free DNA in Men With Advanced Prostate Cancer: Differences in Genomic Landscape Based on Race. Oncologist. 2022 Oct 01; 27(10):e815-e818.
    View PubMed
  59. Hall WA, Karrison TG, Rosenthal SA, Amin MB, Gomella LG, Purdy JA, Sartor AO, Michalski JM, Garzotto MG, Bergom C, Jani AB, Lawton CAF, Simko JP, Moore JK, Gore EM, Lee WR, Nguyen PL, Danielson BL, Sandler HM, Feng FY. The Influence of the Pretreatment Immune State on Response to Radiation Therapy in High-Risk Prostate Cancer: A Validation Study From NRG/RTOG 0521. Int J Radiat Oncol Biol Phys. 2022 Oct 1; 114 (2):266-274 Epub 2022 June 05
    View PubMed
  60. Fanti S, Briganti A, Emmett L, Fizazi K, Gillessen S, Goffin K, Hadaschik BA, Herrmann K, Kunikowska J, Maurer T, MacLennan S, Mottet N, Murphy DG, Oprea-Lager DE, O'Sullivan JM, Oyen WJG, Rouviere O, Sartor O, Stenzl A, Van Poppel H, Walz J, Witjes W, Bjartell A. EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [(177)Lu]Lu-PSMA Radioligand Therapy. Eur Urol Oncol. 2022 Oct; 5 (5):530-536 Epub 2022 June 11
    View PubMed
  61. Pollack A, Karrison TG, Feng F, Sartor O, Sandler HM. The addition of pelvic lymph node treatment to prostate bed salvage radiotherapy - Authors' reply. Lancet 2022 Sep 17; 400 (10356):885-886
    View PubMed
  62. Hussain M, Carducci MA, Clarke N, Fenton SE, Fizazi K, Gillessen S, Jacene H, Morris MJ, Saad F, Sartor O, Taplin ME, Vapiwala N, Williams S, Sweeney C. Evolving Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Hormone-Sensitive Prostate Cancer: More Questions than Answers? J Clin Oncol. 2022 Sep 10; 40 (26):3011-3014 Epub 2022 Apr 19
    View PubMed
  63. Liu AJ, Kosiorek HE, Ueberroth BE, Jaeger E, Ledet E, Kendi AT, Tzou K, Quevedo F, Choo R, Moore CN, Ho TH, Singh P, Keole SR, Wong WW, Sartor O, Bryce AH. The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases. Prostate. 2022 Sep; 82(12):1202-1209. Epub 2022 Jun 02.
    View PubMed
  64. Manogue CE, Chen W, Mazza A, Dang A, Lewis B, Wallis CJD, Layton J, Barata P, Sartor O, Harris KM. Embracing the Practical Aspects of Theranostics With Prostate-Specific Membrane Antigen-Targeted Lutetium-177. Pract Radiat Oncol. 2022 Jul-Aug; 12 (4):300-304 Epub 2022 May 14
    View PubMed
  65. Turco F, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke C, Clarke N, Davis ID, de Bono J, Duran I, Eeles R, Efstathiou E, Efstathiou J, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Heinrich D, Higano C, Hofman MS, Hussain M, James N, Jones R, Kanesvaran R, Khauli RB, Klotz L, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ekeke Onyeanunam N, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin M, Ryan CJ, Saad F, Pablo Sade J, Sartor O, Scher HI, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt D, Sternberg CN, Suzuki H, Sweeney C, Sydes M, Taplin ME, Tilki D, Tombal B, Turkeri L, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zapatero A, Gillessen S, Omlin A. What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. Eur Urol. 2022 Jul; 82 (1):6-11 Epub 2022 Feb 17
    View PubMed
  66. Turco F, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke C, Clarke N, Davis ID, de Bono J, Duran I, Eeles R, Efstathiou E, Efstathiou J, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Heinrich D, Higano C, Hofman MS, Hussain M, James N, Jones R, Kanesvaran R, Khauli RB, Klotz L, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ekeke ON, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin M, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt D, Sternberg CN, Suzuki H, Sweeney C, Sydes M, Taplin ME, Tilki D, Tombal B, Turkeri L, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zapatero A, Gillessen S, Omlin A. Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 82(1):6-11]. Eur Urol. 2022 Jul; 82 (1):e18-e19 Epub 2022 Apr 16
    View PubMed
  67. Gillessen S, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke CS, Clarke N, Davis ID, de Bono JS, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ekeke ON, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Heinrich D, Higano C, Hofman MS, Hussain M, James N, Jones R, Kanesvaran R, Khauli RB, Klotz L, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin M, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt DE, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Taplin ME, Tilki D, Tombal B, Turkeri L, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zapatero A, Omlin A. Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. Eur Urol. 2022 Jul; 82 (1):115-141 Epub 2022 Apr 18
    View PubMed
  68. Sartor O, Herrmann K. Prostate Cancer Treatment: (177)Lu-PSMA-617 Considerations, Concepts, and Limitations. J Nucl Med. 2022 Jun; 63 (6):823-829
    View PubMed
  69. Sentana-Lledo D, Sartor O, Balk SP, Einstein DJ. Immune mechanisms behind prostate cancer in men of African ancestry: A review. Prostate. 2022 Jun; 82 (8):883-893 Epub 2022 Mar 07
    View PubMed
  70. Pollack A, Karrison TG, Balogh AG, Gomella LG, Low DA, Bruner DW, Wefel JS, Martin AG, Michalski JM, Angyalfi SJ, Lukka H, Faria SL, Rodrigues GB, Beauchemin MC, Lee RJ, Seaward SA, Allen AM, Monitto DC, Seiferheld W, Sartor O, Feng F, Sandler HM. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. Lancet. 2022 May 14; 399 (10338):1886-1901
    View PubMed
  71. Reyes DK, Trock BJ, Tran PT, Pavlovich CP, Deville C, Allaf ME, Greco SC, Song DY, Bivalacqua TJ, Han M, Partin AW, Sartor AO, Rowe SP, Pienta KJ. Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancer. Med Oncol. 2022 Apr 28; 39 (5):63
    View PubMed
  72. Hawkey NM, Sartor AO, Morris MJ, Armstrong AJ. Prostate-specific membrane antigen-targeted theranostics: past, present, and future approaches. Clin Adv Hematol Oncol. 2022 Apr; 20 (4):227-238
    View PubMed
  73. Huang S, Cao B, Wang J, Zhang Y, Ledet E, Sartor O, Xiong Y, Zeng SX, Lu H. Cancer-derived C-terminus-extended p53 mutation confers dominant-negative effect on its wild-type counterpart. J Mol Cell Biol. 2022 Mar 29; 14(1).
    View PubMed
  74. Freeman MN, Jang A, Zhu J, Sanati F, Nandagopal L, Ravindranathan D, Desai A, Phone A, Nussenzveig R, Jaeger E, Caputo SA, Koshkin VS, Swami U, Basu A, Bilen MA, Agarwal N, Sartor O, Burgess EF, Barata PC. Multi-institutional Analysis of the Clinical and Genomic Characteristics of Black Patients with Metastatic Hormone-Sensitive Prostate Cancer. Oncologist. 2022 Mar 11; 27 (3):220-227
    View PubMed
  75. Sartor O, Fougere C, Essler M, Ezziddin S, Kramer G, Ellinger J, Nordquist L, Sylvester J, Paganelli G, Peer A, Bogemann M, Meltzer J, Sandstrom P, Verholen F, Song DY. (177)Lu-Prostate-Specific Membrane Antigen Ligand After (223)Ra Treatment in Men with Bone-Metastatic Castration-Resistant Prostate Cancer: Real-World Clinical Experience. J Nucl Med. 2022 Mar; 63 (3):410-414 Epub 2021 June 24
    View PubMed
  76. Maxwell KN, Cheng HH, Powers J, Gulati R, Ledet EM, Morrison C, Le A, Hausler R, Stopfer J, Hyman S, Kohlmann W, Naumer A, Vagher J, Greenberg SE, Naylor L, Laurino M, Konnick EQ, Shirts BH, AlDubayan SH, Van Allen EM, Nguyen B, Vijai J, Abida W, Carlo MI, Dubard-Gault M, Lee DJ, Maese LD, Mandelker D, Montgomery B, Morris MJ, Nicolosi P, Nussbaum RL, Schwartz LE, Stadler Z, Garber JE, Offit K, Schiffman JD, Nelson PS, Sartor O, Walsh MF, Pritchard CC. Inherited TP53 Variants and Risk of Prostate Cancer. Eur Urol. 2022 Mar; 81 (3):243-250 Epub 2021 Dec 01
    View PubMed
  77. Plym A, Diossy M, Szallasi Z, Sartor O, Silberstein J, Powell IJ, Rebbeck TR, Penney KL, Mucci LA, Pomerantz MM, Kibel AS. DNA Repair Pathways and Their Association With Lethal Prostate Cancer in African American and European American Men. JNCI Cancer Spectr. 2022 Feb; 6 (1) Epub 2021 Dec 27
    View PubMed
  78. George DJ, Agarwal N, Sartor O, Sternberg CN, Tombal B, Saad F, Miller K, Constantinovici N, Guo H, Reeves J, Jiao X, Sandstrom P, Verholen F, Higano CS, Shore N. Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study). Prostate Cancer Prostatic Dis. 2022 Feb; 25 (2):306-313 Epub 2022 Feb 21
    View PubMed
  79. Swami U, Zimmerman RM, Nussenzveig RH, Hernandez EJ, Jo Y, Sayegh N, Wesolowski S, Kiedrowski LA, Barata PC, Lemmon GH, Bilen MA, Heath EI, Nandagopal L, Babiker HM, Pal SK, Lilly M, Maughan BL, Haaland B, Yandell M, Sartor O, Agarwal N. Genomic landscape of advanced prostate cancer patients with BRCA1 versus BRCA2 mutations as detected by comprehensive genomic profiling of cell-free DNA. Front Oncol. 2022; 12:966534. Epub 2022 Sep 15.
    View PubMed
  80. Meisel A, de Wit R, Oudard S, Sartor O, Stenner-Liewen F, Shun Z, Foster M, Ozatilgan A, Eisenberger M, de Bono JS. Neutropenia, neutrophilia, and neutrophil-lymphocyte ratio as prognostic markers in patients with metastatic castration-resistant prostate cancer. Ther Adv Med Oncol. 2022; 14:17588359221100022 Epub 2022 June 01
    View PubMed
  81. Sartor O, George D, Tombal B, Agarwal N, Higano CS, Sternberg CN, Miller K, Jiao X, Guo H, Sandstrom P, Bruno A, Verholen F, Saad F, Shore N. Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC. Future Oncol. 2022 Jan; 18 (1):35-45 Epub 2021 Oct 12
    View PubMed
  82. Zhang W, Dong Y, Sartor O, Zhang K. Deciphering the Increased Prevalence of TP53 Mutations in Metastatic Prostate Cancer. Cancer Inform. 2022; 21:11769351221087046 Epub 2022 Apr 02
    View PubMed
  83. Vogl UM, Beer TM, Davis ID, Shore ND, Sweeney CJ, Ost P, Attard G, Bossi A, de Bono J, Drake CG, Efstathiou E, Fanti S, Fizazi K, Halabi S, James N, Mottet N, Padhani AR, Roach M, Rubin M, Oliver, Sartor O, Small E, Smith MR, Soule H, Sydes MR, Tombal B, Omlin A, Gillessen S, APCCC 2019 expert panel. Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings. Eur J Cancer 2022 Jan; 160:24-60 Epub 2021 Nov 26
    View PubMed
  84. Sartor O, Baghian A. Prostate specific membrane antigen binding radiopharmaceuticals: Current data and new concepts. Front Med (Lausanne). 2022; 9:1060922 Epub 2022 Dec 06
    View PubMed
  85. Sokolova AO, Marshall CH, Lozano R, Gulati R, Ledet EM, De Sarkar N, Grivas P, Higano CS, Montgomery B, Nelson PS, Olmos D, Sokolov V, Schweizer MT, Yezefski TA, Yu EY, Paller CJ, Sartor O, Castro E, Antonarakis ES, Cheng HH. Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations. Prostate. 2021 Dec; 81 (16):1382-1389 Epub 2021 Sept 13
    View PubMed
  86. Perry LM, Sartor O, Malhotra S, Alonzi S, Kim S, Voss HM, Rogers JL, Robinson W, Harris K, Shank J, Morrison DG, Lewson AB, Fuloria J, Miele L, Lewis B, Mossman B, Hoerger M. Increasing Readiness for Early Integrated Palliative Oncology Care: Development and Initial Evaluation of the EMPOWER 2 Intervention. J Pain Symptom Manage. 2021 Nov; 62 (5):987-996 Epub 2021 Apr 20
    View PubMed
  87. Herrmann K, Kraus BJ, Hadaschik B, Kunikowska J, van Poppel H, N'Dow J, Sartor O, Oyen WJG. Nuclear medicine theranostics comes of age. Lancet Oncol. 2021 Nov; 22 (11):1497-1498
    View PubMed
  88. Fong L, Morris MJ, Sartor O, Higano CS, Pagliaro L, Alva A, Appleman LJ, Tan W, Vaishampayan U, Porcu R, Tayama D, Kadel EE 3rd, Yuen KC, Datye A, Armstrong AJ, Petrylak DP. A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2021 Sep 01; 27(17):4746-4756. Epub 2021 Jun 09.
    View PubMed
  89. Spratt DE, Shore N, Sartor O, Rathkopf D, Olivier K. Correction: Treating the patient and not just the cancer: therapeutic burden in prostate cancer. Prostate Cancer Prostatic Dis. 2021 Sep; 24 (3):927
    View PubMed
  90. Lin E, Hahn AW, Nussenzveig RH, Wesolowski S, Sayegh N, Maughan BL, McFarland T, Rathi N, Sirohi D, Sonpavde G, Swami U, Kohli M, Rich T, Sartor O, Yandell M, Agarwal N. Identification of Somatic Gene Signatures in Circulating Cell-Free DNA Associated with Disease Progression in Metastatic Prostate Cancer by a Novel Machine Learning Platform. Oncologist. 2021 Sep; 26 (9):751-760 Epub 2021 July 07
    View PubMed
  91. Spratt DE, Shore N, Sartor O, Rathkopf D, Olivier K. Treating the patient and not just the cancer: therapeutic burden in prostate cancer. Prostate Cancer Prostatic Dis. 2021 Sep; 24 (3):647-661 Epub 2021 Feb 18
    View PubMed
  92. George DJ, Halabi S, Heath EI, Sartor AO, Sonpavde GP, Das D, Bitting RL, Berry W, Healy P, Anand M, Winters C, Riggan C, Kephart J, Wilder R, Shobe K, Rasmussen J, Milowsky MI, Fleming MT, Bearden J, Goodman M, Zhang T, Harrison MR, McNamara M, Zhang D, LaCroix BL, Kittles RA, Patierno BM, Sibley AB, Patierno SR, Owzar K, Hyslop T, Freedman JA, Armstrong AJ. A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer. Cancer. 2021 Aug 15; 127(16):2954-2965. Epub 2021 May 05.
    View PubMed
  93. Sumanasuriya S, Seed G, Parr H, Christova R, Pope L, Bertan C, Bianchini D, Rescigno P, Figueiredo I, Goodall J, Fowler G, Flohr P, Mehra N, Neeb A, Rekowski J, Eisenberger M, Sartor O, Oudard S, Geffriaud-Ricouard C, Ozatilgan A, Chadjaa M, Mace S, Lord C, Baxter J, Pettitt S, Lambros M, Sharp A, Mateo J, Carreira S, Yuan W, de Bono JS. Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA. Eur Urol. 2021 Aug; 80 (2):243-253 Epub 2021 June 05
    View PubMed
  94. Bennett CL, Nagai S, Bennett AC, Hoque S, Nabhan C, Schoen MW, Hrushesky WJ, Luminari S, Ray P, Yarnold PR, Witherspoon B, Riente J, Bobolts L, Brusk J, Tombleson R, Knopf K, Fishman M, Yang YT, Carson KR, Djulbegovic B, Restaino J, Armitage JO, Sartor OA. The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions. Oncologist. 2021 Aug; 26 (8):e1418-e1426 Epub 2021 Mar 12
    View PubMed
  95. Zhang W, Dong Y, Sartor O, Zhang K. Comprehensive Analysis of Multiple Cohort Datasets Deciphers the Utility of Germline Single-Nucleotide Polymorphisms in Prostate Cancer Diagnosis. Cancer Prev Res (Phila). 2021 Jul; 14 (7):741-752 Epub 2021 Apr 17
    View PubMed
  96. Thiery-Vuillemin A, Fizazi K, Sartor O, Oudard S, Bury D, Ozatilgan A, Poole EM, Eisenberger M, de Bono J. Post Hoc Health-Related Quality of Life Analysis According to Response Among Patients with Prostate Cancer in the PROSELICA and FIRSTANA Studies. Oncologist. 2021 Jul; 26 (7):e1179-e1188 Epub 2021 May 21
    View PubMed
  97. Sartor O, Appukkuttan S, Weiss J, Tsao CK. Clinical outcomes, management, and treatment patterns in patients with metastatic castration-resistant prostate cancer treated with radium-223 in community compared to academic settings. Prostate. 2021 Jul; 81 (10):657-666 Epub 2021 May 12
    View PubMed
  98. Alonzi S, Hoerger M, Perry LM, Chow LD, Manogue C, Cotogno P, Ernst EM, Ledet EM, Sartor O. Changes in taste and smell of food during prostate cancer treatment. Support Care Cancer. 2021 Jun; 29 (6):2807-2809 Epub 2021 Feb 10
    View PubMed
  99. Ledet EM, Burgess EF, Sokolova AO, Jaeger EB, Hatton W, Moses M, Miller P, Cotogno P, Layton J, Barata P, Lewis BE, Nakazawa M, Zhu J, Dellinger B, Elrefai S, Nafissi NN, Egan JB, Shore N, McKay RR, Bryce AH, Cheng HH, Antonarakis ES, Sartor O. Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer. Prostate. 2021 May; 81(7):433-439. Epub 2021 Apr 01.
    View PubMed
  100. Sabol RA, Ledet EM, Jaeger E, Hatton W, Moses M, Lankford A, Zaheria A, Barata P, Layton JL, Lewis BE, Sartor O. Family history and pathogenic/likely pathogenic germline variants in prostate cancer patients. Prostate. 2021 May; 81 (7):427-432 Epub 2021 Mar 24
    View PubMed
  101. Denmeade SR, Wang H, Agarwal N, Smith DC, Schweizer MT, Stein MN, Assikis V, Twardowski PW, Flaig TW, Szmulewitz RZ, Holzbeierlein JM, Hauke RJ, Sonpavde G, Garcia JA, Hussain A, Sartor O, Mao S, Cao H, Fu W, Wang T, Abdallah R, Lim SJ, Bolejack V, Paller CJ, Carducci MA, Markowski MC, Eisenberger MA, Antonarakis ES. TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer. J Clin Oncol. 2021 Apr 20; 39 (12):1371-1382 Epub 2021 Feb 22
    View PubMed
  102. Petrylak DP, Vaishampayan UN, Patel KR, Higano CS, Albany C, Dawson NA, Mehlhaff BA, Quinn DI, Nordquist LT, Wagner VJ, Siegel J, Trandafir L, Sartor O. A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide. ESMO Open. 2021 Apr; 6 (2):100082 Epub 2021 Mar 19
    View PubMed
  103. Thiery-Vuillemin A, Fizazi K, Sartor O, Oudard S, Bury D, Thangavelu K, Ozatilgan A, Poole EM, Eisenberger M, de Bono J. An analysis of health-related quality of life in the phase III PROSELICA and FIRSTANA studies assessing cabazitaxel in patients with metastatic castration-resistant prostate cancer. ESMO Open. 2021 Apr; 6 (2):100089 Epub 2021 Mar 16
    View PubMed
  104. Marshall CH, Fu W, Wang H, Park JC, DeWeese TL, Tran PT, Song DY, King S, Afful M, Hurrelbrink J, Manogue C, Cotogno P, Moldawer NP, Barata PC, Drake CG, Posadas EM, Armstrong AJ, Sartor O, Antonarakis ES. Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer. Clin Cancer Res. 2021 Mar 15; 27 (6):1623-1630 Epub 2021 Jan 15
    View PubMed
  105. Delanoy N, Robbrecht D, Eisenberger M, Sartor O, de Wit R, Mercier F, Geffriaud-Ricouard C, de Bono J, Oudard S. Pain Progression at Initiation of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Post Hoc Analysis of the PROSELICA Study. Cancers (Basel). 2021 Mar 13; 13 (6)
    View PubMed
  106. Chabner BA, Bates SE, Fojo AT, Murphy A, Sartor AO, Murphy MJ. A Medical Pearl Harbor: Pandemic Uncovers Societal Fissures and Leadership Breaches. Oncologist. 2021 Feb; 26 (2):89 Epub 2021 Jan 16
    View PubMed
  107. Greenberg JW, Leinwand G, Feibus AH, Haney NM, Krane LS, Thomas R, Sartor O, Silberstein JL. Prospective Observational Study of a Racially Diverse Group of Men on Active Surveillance for Prostate Cancer. Urology. 2021 Feb; 148:203-210 Epub 2020 Nov 07
    View PubMed
  108. Sartor O, Hope TA, Calais J, Fendler WP. Oliver Sartor Talks with Thomas A. Hope, Jeremie Calais, and Wolfgang P. Fendler About FDA Approval of PSMA. J Nucl Med. 2021 Feb; 62 (2):146-148
    View PubMed
  109. Morgans AK, Shore N, Cope D, McNatty A, Moslehi J, Gomella L, Sartor O. Androgen receptor inhibitor treatments: Cardiovascular adverse events and comorbidity considerations in patients with non-metastatic prostate cancer. Urol Oncol. 2021 Jan; 39(1):52-62. Epub 2020 Sep 18.
    View PubMed
  110. Taza F, Holler AE, Fu W, Wang H, Adra N, Albany C, Ashkar R, Cheng HH, Sokolova AO, Agarwal N, Kessel A, Bryce A, Nafissi N, Barata P, Sartor AO, Bastos D, Smaletz O, Berchuck JE, Taplin ME, Aggarwal R, Sternberg CN, Vlachostergios PJ, Alva AS, Su C, Marshall CH, Antonarakis ES. Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer. JCO Precis Oncol. 2021; 5. Epub 2021 Jul 22.
    View PubMed
  111. Marima R, Hull R, Mathabe K, Setlai B, Batra J, Sartor O, Mehrotra R, Dlamini Z. Prostate cancer racial, socioeconomic, geographic disparities: targeting the genomic landscape and splicing events in search for diagnostic, prognostic and therapeutic targets. Am J Cancer Res. 2021; 11 (4):1012-1030 Epub 2021 Apr 15
    View PubMed
  112. Liu S, Zhang B, Rowan BG, Jazwinski SM, Abdel-Mageed AB, Steele C, Wang AR, Sartor O, Niu T, Zhang Q. A Novel Controlled PTEN-Knockout Mouse Model for Prostate Cancer Study. Front Mol Biosci. 2021; 8:696537 Epub 2021 June 03
    View PubMed
  113. Bennett CL, Hoque S, Olivieri N, Taylor MA, Aboulafia D, Lubaczewski C, Bennett AC, Vemula J, Schooley B, Witherspoon BJ, Godwin AC, Ray PS, Yarnold PR, Ausdenmoore HC, Fishman M, Herring G, Ventrone A, Aldaco J, Hrushesky WJ, Restaino J, Thomsen HS, Yarnold PR, Marx R, Migliorati C, Ruggiero S, Nabhan C, Carson KR, McKoy JM, Yang YT, Schoen MW, Knopf K, Martin L, Sartor O, Rosen S, Smith WK. Consequences to patients, clinicians, and manufacturers when very serious adverse drug reactions are identified (1997-2019): A qualitative analysis from the Southern Network on Adverse Reactions (SONAR). EClinicalMedicine. 2021 Jan; 31:100693 Epub 2020 Dec 23
    View PubMed
  114. Risdon EN, Chau CH, Price DK, Sartor O, Figg WD. PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA. Oncologist. 2021 Jan; 26 (1):e115-e129 Epub 2020 Sept 08
    View PubMed
  115. Sugimoto M, Hong JH, Kwon TG, Lee JY, Dawson N, Patel K, Zhang J, Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Roubaud G, Ozguroglu M, Kang J, Burgents J, Gresty C, Corcoran C, Adelman CA, de Bono J, PROfound Trial Investigators. Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020 Dec 10; 383 (24):2345-2357 Epub 2020 Sept 20
    View PubMed
  116. Shore N, Higano CS, George DJ, Sternberg CN, Saad F, Tombal B, Miller K, Kalinovsky J, Jiao X, Tangirala K, Sartor O. Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2020 Dec; 23 (4):680-688 Epub 2020 May 13
    View PubMed
  117. Jang A, Sartor O, Barata PC, Paller CJ. Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer. Cancers (Basel). 2020 Nov 21; 12 (11)
    View PubMed
  118. Schmid S, Omlin A, Higano C, Sweeney C, Martinez Chanza N, Mehra N, Kuppen MCP, Beltran H, Conteduca V, Vargas Pivato de Almeida D, Cotait Maluf F, Oh WK, Tsao CK, Sartor O, Ledet E, Di Lorenzo G, Yip SM, Chi KN, Bianchini D, De Giorgi U, Hansen AR, Beer TM, Lavaud P, Morales-Barrera R, Tucci M, Castro E, Karalis K, Bergman AM, Le ML, Zurrer-Hardi U, Pezaro C, Suzuki H, Zivi A, Klingbiel D, Schar S, Gillessen S. Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. JAMA Netw Open. 2020 Oct 1; 3 (10):e2021692 Epub 2020 Oct 01
    View PubMed
  119. Xie W, Regan MM, Buyse M, Halabi S, Kantoff PW, Sartor O, Soule H, Berry D, Clarke N, Collette L, D'Amico A, Lourenco RA, Dignam J, Eisenberger M, James N, Fizazi K, Gillessen S, Loriot Y, Mottet N, Parulekar W, Sandler H, Spratt DE, Sydes MR, Tombal B, Williams S, Sweeney CJ, ICECaP Working Group. Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation. J Clin Oncol. 2020 Sep 10; 38 (26):3032-3041 Epub 2020 June 18
    View PubMed
  120. Sartor O, Armstrong AJ, Ahaghotu C, McLeod DG, Cooperberg MR, Penson DF, Kantoff PW, Vogelzang NJ, Hussain A, Pieczonka CM, Shore ND, Quinn DI, Small EJ, Heath EI, Tutrone RF, Schellhammer PF, Harmon M, Chang NN, Sheikh NA, Brown B, Freedland SJ, Higano CS. Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry. Prostate Cancer Prostatic Dis. 2020 Sep; 23(3):517-526. Epub 2020 Feb 28.
    View PubMed
  121. Giri VN, Knudsen KE, Kelly WK, Cheng HH, Cooney KA, Cookson MS, Dahut W, Weissman S, Soule HR, Petrylak DP, Dicker AP, AlDubayan SH, Toland AE, Pritchard CC, Pettaway CA, Daly MB, Mohler JL, Parsons JK, Carroll PR, Pilarski R, Blanco A, Woodson A, Rahm A, Taplin ME, Polascik TJ, Helfand BT, Hyatt C, Morgans AK, Feng F, Mullane M, Powers J, Concepcion R, Lin DW, Wender R, Mark JR, Costello A, Burnett AL, Sartor O, Isaacs WB, Xu J, Weitzel J, Andriole GL, Beltran H, Briganti A, Byrne L, Calvaresi A, Chandrasekar T, Chen DYT, Den RB, Dobi A, Crawford ED, Eastham J, Eggener S, Freedman ML, Garnick M, Gomella PT, Handley N, Hurwitz MD, Izes J, Karnes RJ, Lallas C, Languino L, Loeb S, Lopez AM, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann M, Mille P, Miner MM, Morgan T, Moreno J, Mucci L, Myers RE, Nielsen SM, O'Neil B, Pinover W, Pinto P, Poage W, Raj GV, Rebbeck TR, Ryan C, Sandler H, Schiewer M, Scott EMD, Szymaniak B, Tester W, Trabulsi EJ, Vapiwala N, Yu EY, Zeigler-Johnson C, Gomella LG. Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. J Clin Oncol. 2020 Aug 20; 38 (24):2798-2811 Epub 2020 June 09
    View PubMed
  122. Barata P, Agarwal N, Nussenzveig R, Gerendash B, Jaeger E, Hatton W, Ledet E, Lewis B, Layton J, Babiker H, Bryce A, Garje R, Stein C, Kiedrowski L, Saylor P, Sartor O. Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA. J Immunother Cancer. 2020 Aug; 8(2).
    View PubMed
  123. George DJ, Sartor O, Miller K, Saad F, Tombal B, Kalinovsky J, Jiao X, Tangirala K, Sternberg CN, Higano CS. Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States. Clin Genitourin Cancer. 2020 Aug; 18 (4):284-294 Epub 2020 Jan 07
    View PubMed
  124. Liu S, Liu F, Zhang B, Yan P, Rowan BG, Abdel-Mageed AB, Steele C, Jazwinski SM, Moroz K, Norton EB, Wang A, Myers L, Sartor O, Zhang Q. CD4(+) T helper 17 cell response of aged mice promotes prostate cancer cell migration and invasion. Prostate. 2020 Jul; 80 (10):764-776 Epub 2020 May 01
    View PubMed
  125. Steinwald P, Ledet E, Sartor O. Eradication of BRAF K601E Mutation in Metastatic Castrate-resistant Prostate Cancer Treated With Cabazitaxel and Carboplatin: A Case Report. Clin Genitourin Cancer. 2020 Jun; 18 (3):e312-e314 Epub 2019 Dec 19
    View PubMed
  126. Vidula N, Rich TA, Sartor O, Yen J, Hardin A, Nance T, Lilly MB, Nezami MA, Patel SP, Carneiro BA, Fan AC, Brufsky AM, Parker BA, Bridges BB, Agarwal N, Maughan BL, Raymond VM, Fairclough SR, Lanman RB, Bardia A, Cristofanilli M. Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion BRCA Mutations among Patients with Advanced Solid Tumors. Clin Cancer Res. 2020 Jun 1; 26 (11):2546-2555 Epub 2020 Feb 07
    View PubMed
  127. de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Mehra N, Goessl C, Kang J, Burgents J, Wu W, Kohlmann A, Adelman CA, Hussain M. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020 May 28; 382 (22):2091-2102 Epub 2020 Apr 28
    View PubMed
  128. Schoen MW, Hoque S, Witherspoon BJ, Schooley B, Sartor O, Yang YT, Yarnold PR, Knopf KB, Hrushesky WJM, Dickson M, Chen BJ, Nabhan C, Bennett CL. End of an era for erythropoiesis-stimulating agents in oncology. Int J Cancer. 2020 May 15; 146 (10):2829-2835 Epub 2020 Feb 28
    View PubMed
  129. Dess RT, Sun Y, Jackson WC, Jairath NK, Kishan AU, Wallington DG, Mahal BA, Stish BJ, Zumsteg ZS, Den RB, Hall WA, Gharzai LA, Jaworski EM, Reichert ZR, Morgan TM, Mehra R, Schaeffer EM, Sartor O, Nguyen PL, Lee WR, Rosenthal SA, Michalski JM, Schipper MJ, Dignam JJ, Pisansky TM, Zietman AL, Sandler HM, Efstathiou JA, Feng FY, Shipley WU, Spratt DE. Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer. JAMA Oncol. 2020 May 1; 6 (5):735-743
    View PubMed
  130. Zhang W, Dong Y, Sartor O, Flemington EK, Zhang K. SEER and Gene Expression Data Analysis Deciphers Racial Disparity Patterns in Prostate Cancer Mortality and the Public Health Implication. Sci Rep. 2020 Apr 22; 10 (1):6820
    View PubMed
  131. Chapman L, Ledet EM, Barata PC, Cotogno P, Manogue C, Moses M, Christensen BR, Steinwald P, Ranasinghe L, Layton JL, Lewis BE, Sartor O. TP53 Gain-of-Function Mutations in Circulating Tumor DNA in Men With Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2020 Apr; 18 (2):148-154 Epub 2019 Nov 06
    View PubMed
  132. Ledet EM, Lilly MB, Sonpavde G, Lin E, Nussenzveig RH, Barata PC, Yandell M, Nagy RJ, Kiedrowski L, Agarwal N, Sartor O. Comprehensive Analysis of AR Alterations in Circulating Tumor DNA from Patients with Advanced Prostate Cancer. Oncologist. 2020 Apr; 25 (4):327-333 Epub 2019 Nov 11
    View PubMed
  133. Gillessen S, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Chi KN, Clarke N, Davis ID, de Bono J, Drake CG, Duran I, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Heinrich D, Higano CTS, Hofman MS, Hussain M, James N, Kanesvaran R, Kantoff P, Khauli RB, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Reiter RE, Roach M, Rubin M, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Shore N, Small E, Smith M, Soule H, Sternberg CN, Steuber T, Suzuki H, Sweeney C, Sydes MR, Taplin ME, Tombal B, Turkeri L, van Oort I, Zapatero A, Omlin A. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol 2020 Apr; 77 (4):508-547 Epub 2020 Jan 27
    View PubMed
  134. Ledet EM, Antonarakis ES, Isaacs WB, Lotan TL, Pritchard C, Sartor AO. Germline BLM mutations and metastatic prostate cancer. Prostate. 2020 Feb; 80 (2):235-237 Epub 2019 Nov 05
    View PubMed
  135. Terrisse S, Karamouza E, Parker CC, Sartor AO, James ND, Pirrie S, Collette L, Tombal BF, Chahoud J, Smeland S, Erikstein B, Pignon JP, Fizazi K, Le Teuff G, MORPHEP Collaborative Group. Overall Survival in Men With Bone Metastases From Castration-Resistant Prostate Cancer Treated With Bone-Targeting Radioisotopes: A Meta-analysis of Individual Patient Data From Randomized Clinical Trials. JAMA Oncol. 2020 Feb 1; 6 (2):206-216
    View PubMed
  136. Sartor O, Yang S, Ledet E, Moses M, Nicolosi P. Inherited DNA-repair gene mutations in African American men with prostate cancer. Oncotarget. 2020 Jan 28; 11 (4):440-442
    View PubMed
  137. Moses M, Koksal U, Ledet E, Manogue C, Cotogno P, Lewis B, Layton J, Sartor AO, Barata P. Evaluation of the genomic alterations in the androgen receptor gene during treatment with high-dose testosterone for metastatic castrate-resistant prostate cancer. Oncotarget. 2020 Jan 07; 11(1):15-21.
    View PubMed
  138. Petrylak DP, Vogelzang NJ, Chatta K, Fleming MT, Smith DC, Appleman LJ, Hussain A, Modiano M, Singh P, Tagawa ST, Gore I, McClay EF, Mega AE, Sartor AO, Somer B, Wadlow R, Shore ND, Olson WC, Stambler N, DiPippo VA, Israel RJ. PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study. Prostate. 2020 Jan; 80 (1):99-108 Epub 2019 Nov 19
    View PubMed
  139. Antonarakis ES, Isaacsson Velho P, Fu W, Wang H, Agarwal N, Sacristan Santos V, Maughan BL, Pili R, Adra N, Sternberg CN, Vlachostergios PJ, Tagawa ST, Bryce AH, McNatty AL, Reichert ZR, Dreicer R, Sartor O, Lotan TL, Hussain M. CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors. JCO Precis Oncol. 2020; 4:370-381 Epub 2020 Apr 21
    View PubMed
  140. Perry LM, Hoerger M, Sartor O, Robinson WR. Distress among African American and White adults with cancer in Louisiana. J Psychosoc Oncol. 2020 Jan-Feb; 38 (1):63-72 Epub 2019 July 19
    View PubMed
  141. Moses M, Niu A, Lilly MB, Hahn AW, Nussenzveig R, Ledet E, Manogue C, Cotogno P, Lewis B, Layton J, Agarwal N, Sartor O, Barata PC. Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer. Cancer Treat Res Commun. 2020; 24:100193 Epub 2020 July 14
    View PubMed
  142. Barata P, Hatton W, Desai A, Koshkin V, Jaeger E, Manogue C, Cotogno P, Light M, Lewis B, Layton J, Sartor O, Basu A, Kilari D, Emamekhoo H, Bilen MA. Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort. Front Oncol. 2020; 10:581189 Epub 2020 Oct 22
    View PubMed
  143. Robbrecht DG, Delanoy N, Tannock IF, Tombal B, Eisenberger M, Fizazi K, Sartor O, Mercier F, Oudard S, de Wit R. Impact of progression at baseline and on-treatment progression events in three large prostate cancer trials. Eur J Cancer. 2020 Jan; 125:142-152. Epub 2019 Dec 11.
    View PubMed
  144. Barata P, Layton J, Lewis B, Sartor O. Next Generation of Androgen Deprivation Therapy Combined With Radiotherapy for N0 M0 Prostate Cancer. Cancer J. 2020 Jan/Feb; 26 (1):21-28
    View PubMed
  145. Koksal UI, Goffin J, Lewis B, Sartor OA, Belyaeva E, Socola F, Barata PC. A Case Report with Severe Thrombocytopenia Induced by Axitinib. Case Rep Hematol. 2020; 2020:7520783 Epub 2020 Feb 07
    View PubMed
  146. Hoque S, Chen BJ, Schoen MW, Carson KR, Keller J, Witherspoon BJ, Knopf KB, Yang YT, Schooley B, Nabhan C, Sartor O, Yarnold PR, Ray P, Bobolts L, Hrushesky WJ, Dickson M, Bennett CL. End of an era of administering erythropoiesis stimulating agents among Veterans Administration cancer patients with chemotherapy-induced anemia. PLoS One. 2020; 15 (6):e0234541 Epub 2020 June 25
    View PubMed
  147. Kaul T, Morales ME, Sartor AO, Belancio VP, Deininger P. Comparative analysis on the expression of L1 loci using various RNA-Seq preparations. Mob DNA. 2020; 11:2 Epub 2020 Jan 06
    View PubMed
  148. Christensen BR, Barata PC, Ledet EM, Layton JL, Lewis BE, Sartor O. High-Dose Testosterone and Radium-223 Response in Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2019 Dec; 17 (6):476-479 Epub 2019 Aug 19
    View PubMed
  149. Higano CS, Armstrong AJ, Sartor AO, Vogelzang NJ, Kantoff PW, McLeod DG, Pieczonka CM, Penson DF, Shore ND, Vacirca J, Concepcion RS, Tutrone RF, Nordquist LT, Quinn DI, Kassabian V, Scholz MC, Harmon M, Tyler RC, Chang NN, Tang H, Cooperberg MR. Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer. Cancer. 2019 Dec 1; 125 (23):4172-4180 Epub 2019 Sept 04
    View PubMed
  150. Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, Halabi S, Nelson PS, Sartor O, Smith MR, Soule HR, Akaza H, Beer TM, Beltran H, Chinnaiyan AM, Daugaard G, Davis ID, De Santis M, Drake CG, Eeles RA, Fanti S, Gleave ME, Heidenreich A, Hussain M, James ND, Lecouvet FE, Logothetis CJ, Mastris K, Nilsson S, Oh WK, Olmos D, Padhani AR, Parker C, Rubin MA, Schalken JA, Scher HI, Sella A, Shore ND, Small EJ, Sternberg CN, Suzuki H, Sweeney CJ, Tannock IF, Tombal B. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol. 2019 Dec; 30 (12):e3 Epub 2016 May 02
    View PubMed
  151. Muralidhar V, Zhang J, Wang Q, Mahal BA, Butler SS, Spratt DE, Davicioni E, Sartor O, Feng FY, Mouw KW, Nguyen PL. Genomic Validation of 3-Tiered Clinical Subclassification of High-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2019 Nov 1; 105 (3):621-627 Epub 2019 July 02
    View PubMed
  152. Cao S, Ma T, Ungerleider N, Roberts C, Kobelski M, Jin L, Concha M, Wang X, Baddoo M, Nguyen HM, Corey E, Fazli L, Ledet E, Zhang R, Silberstein JL, Zhang W, Zhang K, Sartor O, Dong X, Flemington EK, Dong Y. Circular RNAs add diversity to androgen receptor isoform repertoire in castration-resistant prostate cancer. Oncogene. 2019 Nov; 38 (45):7060-7072 Epub 2019 Aug 13
    View PubMed
  153. De Vincentis G, Gerritsen W, Gschwend JE, Hacker M, Lewington V, O'Sullivan JM, Oya M, Pacilio M, Parker C, Shore N, Sartor O, Targeted Alpha Therapy Prostate Working Group. Advances in targeted alpha therapy for prostate cancer. Ann Oncol. 2019 Nov 1; 30 (11):1728-1739
    View PubMed
  154. Sartor O, Heinrich D, Mariados N, Mendez Vidal MJ, Keizman D, Thellenberg Karlsson C, Peer A, Procopio G, Frank SJ, Pulkkanen K, Rosenbaum E, Severi S, Trigo J, Trandafir L, Wagner V, Li R, Nordquist LT. Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases. Prostate. 2019 Oct; 79 (14):1683-1691 Epub 2019 Aug 23
    View PubMed
  155. Gomez Rivas J, Carrion DM, Alvarez-Maestro M, Cathelineau X, Sanchez-Salas R, Di Lorenzo G, Di Maio M, Paul A, Martinez-Pineiro L, Sartor O, Saad F, Debruyne F. Bone-targeted therapy in castration-resistant prostate cancer: where do we stand? Minerva Urol Nefrol. 2019 Oct; 71 (5):445-456 Epub 2019 July 25
    View PubMed
  156. Sartor O, Nicolosi P, Nussbaum RL. Germline Variants in Highly Selected Patients With Prostate Cancer-In Reply. JAMA Oncol. 2019 Sep 1; 5 (9):1369
    View PubMed
  157. Barata PC, Sartor AO. Metastatic castration-sensitive prostate cancer: Abiraterone, docetaxel, or.... Cancer. 2019 Jun 1; 125 (11):1777-1788 Epub 2019 Apr 01
    View PubMed
  158. Schiff JP, Cotogno P, Feibus A, Steinwald P, Ledet E, Lewis B, Sartor O. Early prostate-specific antigen response post-abiraterone as predictor of overall survival in metastatic castrate-resistant prostate cancer. BMC Cancer. 2019 May 31; 19 (1):524
    View PubMed
  159. Rosenthal SA, Hu C, Sartor O, Gomella LG, Amin MB, Purdy J, Michalski JM, Garzotto MG, Pervez N, Balogh AG, Rodrigues GB, Souhami L, Reaume MN, Williams SG, Hannan R, Horwitz EM, Raben A, Peters CA, Feng FY, Shipley WU, Sandler HM. Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial. J Clin Oncol. 2019 May 10; 37 (14):1159-1168 Epub 2019 Mar 12
    View PubMed
  160. Sonpavde G, Agarwal N, Pond GR, Nagy RJ, Nussenzveig RH, Hahn AW, Sartor O, Gourdin TS, Nandagopal L, Ledet EM, Naik G, Armstrong AJ, Wang J, Bilen MA, Gupta S, Grivas P, Pal SK, Lanman RB, Talasaz A, Lilly MB. Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer. Cancer. 2019 May 1; 125 (9):1459-1469 Epub 2019 Jan 08
    View PubMed
  161. Chen B, Nagai S, Armitage JO, Witherspoon B, Nabhan C, Godwin AC, Yang YT, Kommalapati A, Tella SH, DeAngelis C, Raisch DW, Sartor O, Hrushesky WJ, Ray PS, Yarnold PR, Love BL, Norris LB, Knopf K, Bobolts L, Riente J, Luminari S, Kane RC, Hoque S, Bennett CL. Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada. Oncologist. 2019 Apr; 24(4):537-548. Epub 2019 Mar 06.
    View PubMed
  162. Nicolosi P, Ledet E, Yang S, Michalski S, Freschi B, O'Leary E, Esplin ED, Nussbaum RL, Sartor O. Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines. JAMA Oncol. 2019 Apr 1; 5 (4):523-528
    View PubMed
  163. Manogue C, Cotogno P, Ledet E, Lewis B, Wyatt AW, Sartor O. Biomarkers for Programmed Death-1 Inhibition in Prostate Cancer. Oncologist. 2019 Apr; 24 (4):444-448 Epub 2018 Dec 12
    View PubMed
  164. Layton JL, Lewis B, Ryan C, Beer TM, Sartor O. Recycling Discarded Drugs: Improving Access to Oral Antineoplastic Drugs. Oncologist. 2019 Mar; 24 (3):291-292 Epub 2018 Dec 19
    View PubMed
  165. Taavitsainen S, Annala M, Ledet E, Beja K, Miller PJ, Moses M, Nykter M, Chi KN, Sartor O, Wyatt AW. Evaluation of Commercial Circulating Tumor DNA Test in Metastatic Prostate Cancer. JCO Precis Oncol. 2019; 3 Epub 2019 June 12
    View PubMed
  166. Bennett CL, Schooley B, Taylor MA, Witherspoon BJ, Godwin A, Vemula J, Ausdenmoore HC, Sartor O, Yang YT, Armitage JO, Hrushesky WJ, Restaino J, Thomsen HS, Yarnold PR, Young T, Knopf KB, Chen B. Caveat Medicus: Clinician experiences in publishing reports of serious oncology-associated adverse drug reactions. PLoS One. 2019; 14 (7):e0219521 Epub 2019 July 31
    View PubMed
  167. Ranasinghe L, Cotogno P, Ledet E, Bordlee B, Degeyter K, Nguyen N, Steinberger A, Manogue C, Barata P, Lewis BE, Sartor AO. Relationship between serum markers and volume of liver metastases in castration-resistant prostate cancer. Cancer Treat Res Commun. 2019; 20:100151 Epub 2019 May 14
    View PubMed
  168. Sartor O. Advanced prostate cancer update 2018. Asia Pac J Clin Oncol. 2018 Nov; 14 Suppl 5:9-12
    View PubMed
  169. Heinrich D, Bruland O, Guise TA, Suzuki H, Sartor O. Alkaline phosphatase in metastatic castration-resistant prostate cancer: reassessment of an older biomarker. Future Oncol. 2018 Oct; 14 (24):2543-2556 Epub 2018 June 21
    View PubMed
  170. Mehra N, Dolling D, Sumanasuriya S, Christova R, Pope L, Carreira S, Seed G, Yuan W, Goodall J, Hall E, Flohr P, Boysen G, Bianchini D, Sartor O, Eisenberger MA, Fizazi K, Oudard S, Chadjaa M, Mace S, de Bono JS. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA). Eur Urol. 2018 Sep; 74 (3):283-291 Epub 2018 Feb 28
    View PubMed
  171. Thomas HR, Chen MH, D'Amico AV, Bennett CL, Kattan MW, Sartor O, Stein K, Nguyen PL. Association Between Androgen Deprivation Therapy and Patient-reported Depression in Men With Recurrent Prostate Cancer. Clin Genitourin Cancer. 2018 Aug; 16 (4):313-317 Epub 2018 June 01
    View PubMed
  172. Miyahira AK, Pienta KJ, Morris MJ, Bander NH, Baum RP, Fendler WP, Goeckeler W, Gorin MA, Hennekes H, Pomper MG, Sartor O, Tagawa ST, Williams S, Soule HR. Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group. Prostate. 2018 Aug; 78 (11):775-789 Epub 2018 May 01
    View PubMed
  173. Cotogno PM, Ranasinghe LK, Ledet EM, Lewis BE, Sartor O. Laboratory-Based Biomarkers and Liver Metastases in Metastatic Castration-Resistant Prostate Cancer. Oncologist. 2018 Jul; 23 (7):791-797 Epub 2018 Apr 26
    View PubMed
  174. Sartor O, Sharma D. Radium and other alpha emitters in prostate cancer. Transl Androl Urol. 2018 Jun; 7 (3):436-444
    View PubMed
  175. Cheng H, Powers J, Schaffer K, Sartor O. Practical Methods for Integrating Genetic Testing Into Clinical Practice for Advanced Prostate Cancer. Am Soc Clin Oncol Educ Book. 2018 May 23; 38:372-381
    View PubMed
  176. Perry LM, Hoerger M, Silberstein J, Sartor O, Duberstein P. Understanding the distressed prostate cancer patient: Role of personality. Psychooncology. 2018 Mar; 27 (3):810-816 Epub 2017 Dec 07
    View PubMed
  177. Manogue C, Ledet E, Guddati AK, Lewis B, Sartor O. Extreme Prostate-Specific Antigen Response to Infusional 5-Flourouracil in Castrate-Resistant Prostate Cancer. Oncologist. 2018 Mar; 23 (3):383-385 Epub 2017 Dec 19
    View PubMed
  178. Valicenti RK, Pugh SL, Trabulsi EJ, Sartor O, Ko EC, Girvigian MR, Rosenthal SA, Shaves ME, Hoffman-Censits JH, Schallenkamp J, Sandler HM. First Report of NRG Oncology/Radiation Therapy Oncology Group 0622: A Phase 2 Trial of Samarium-153 Followed by Salvage Prostatic Fossa Irradiation in High-Risk Clinically Nonmetastatic Prostate Cancer After Radical Prostatectomy. Int J Radiat Oncol Biol Phys. 2018 Mar 1; 100 (3):695-701 Epub 2017 Nov 21
    View PubMed
  179. Parker CC, Coleman RE, Sartor O, Vogelzang NJ, Bottomley D, Heinrich D, Helle SI, O'Sullivan JM, Fossa SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franzen L, Bruland OS, Petrenciuc O, Staudacher K, Li R, Nilsson S. Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial. Eur Urol. 2018 Mar; 73 (3):427-435 Epub 2017 July 11
    View PubMed
  180. Sartor O, de Bono JS. Metastatic Prostate Cancer. N Engl J Med. 2018 Feb 15; 378 (7):645-657 Epub 2018 Feb 07
    View PubMed
  181. Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett A, Catalona WJ, Cooney KA, Cooperberg M, Crawford DE, Den RB, Dicker AP, Eggener S, Fleshner N, Freedman ML, Hamdy FC, Hoffman-Censits J, Hurwitz MD, Hyatt C, Isaacs WB, Kane CJ, Kantoff P, Karnes RJ, Karsh LI, Klein EA, Lin DW, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann MJ, Mark JR, McCue PA, Miner MM, Morgan T, Moul JW, Myers RE, Nielsen SM, Obeid E, Pavlovich CP, Peiper SC, Penson DF, Petrylak D, Pettaway CA, Pilarski R, Pinto PA, Poage W, Raj GV, Rebbeck TR, Robson ME, Rosenberg MT, Sandler H, Sartor O, Schaeffer E, Schwartz GF, Shahin MS, Shore ND, Shuch B, Soule HR, Tomlins SA, Trabulsi EJ, Uzzo R, Vander Griend DJ, Walsh PC, Weil CJ, Wender R, Gomella LG. Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. J Clin Oncol. 2018 Feb 1; 36 (4):414-424 Epub 2017 Dec 13
    View PubMed
  182. Sartor O, Vogelzang NJ, Sweeney C, Fernandez DC, Almeida F, Iagaru A, Brown A Jr, Smith MR, Agrawal M, Dicker AP, Garcia JA, Lutzky J, Wong YN, Petrenciuc O, Gratt J, Shore ND, Morris MJ, U.S. Expanded Access Program Investigators. Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program. Oncologist. 2018 Feb; 23 (2):193-202 Epub 2017 Nov 28
    View PubMed
  183. Summers N, Vanderpuye-Orgle J, Reinhart M, Gallagher M, Sartor O. Efficacy and safety of post-docetaxel therapies in metastatic castration-resistant prostate cancer: a systematic review of the literature. Curr Med Res Opin. 2017 Nov; 33 (11):1995-2008 Epub 2017 July 10
    View PubMed
  184. Seyednasrollah F, Koestler DC, Wang T, Piccolo SR, Vega R, Greiner R, Fuchs C, Gofer E, Kumar L, Wolfinger RD, Kanigel Winner K, Bare C, Neto EC, Yu T, Shen L, Abdallah K, Norman T, Stolovitzky G, Soule HR, Sweeney CJ, Ryan CJ, Scher HI, Sartor O, Elo LL, Zhou FL, Guinney J, Costello JC, Prostate Cancer DREAM Challenge Community. A DREAM Challenge to Build Prediction Models for Short-Term Discontinuation of Docetaxel in Metastatic Castration-Resistant Prostate Cancer. JCO Clin Cancer Inform. 2017 Nov; 1:1-15
    View PubMed
  185. Sartor O, Heinrich D, Mariados N, Mendez Vidal MJ, Keizman D, Thellenberg Karlsson C, Peer A, Procopio G, Frank SJ, Pulkkanen K, Rosenbaum E, Severi S, Trigo Perez JM, Wagner V, Li R, Nordquist LT. Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases. Ann Oncol. 2017 Oct 1; 28 (10):2464-2471
    View PubMed
  186. Oudard S, Fizazi K, Sengelov L, Daugaard G, Saad F, Hansen S, Hjalm-Eriksson M, Jassem J, Thiery-Vuillemin A, Caffo O, Castellano D, Mainwaring PN, Bernard J, Shen L, Chadjaa M, Sartor O. Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA. J Clin Oncol. 2017 Oct 1; 35 (28):3189-3197 Epub 2017 July 28
    View PubMed
  187. Xie W, Regan MM, Buyse M, Halabi S, Kantoff PW, Sartor O, Soule H, Clarke NW, Collette L, Dignam JJ, Fizazi K, Paruleker WR, Sandler HM, Sydes MR, Tombal B, Williams SG, Sweeney CJ, ICECaP Working Group. Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer. J Clin Oncol. 2017 Sep 20; 35 (27):3097-3104 Epub 2017 Aug 10
    View PubMed
  188. Pomerantz MM, Spisak S, Jia L, Cronin AM, Csabai I, Ledet E, Sartor AO, Rainville I, O'Connor EP, Herbert ZT, Szallasi Z, Oh WK, Kantoff PW, Garber JE, Schrag D, Kibel AS, Freedman ML. The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer. Cancer. 2017 Sep 15; 123 (18):3532-3539 Epub 2017 June 13
    View PubMed
  189. Sabol RA, Noxon V, Sartor O, Berger JR, Qureshi Z, Raisch DW, Norris LB, Yarnold PR, Georgantopoulos P, Hrushesky WJ, Bobolts L, Ray P, Lebby A, Kane RC, Bennett CL. Melanoma complicating treatment with natalizumab for multiple sclerosis: A report from the Southern Network on Adverse Reactions (SONAR). Cancer Med. 2017 Jul; 6 (7):1541-1551 Epub 2017 June 20
    View PubMed
  190. Hurwitz MD, Harris J, Sartor O, Xiao Y, Shayegan B, Sperduto PW, Badiozamani KR, Lawton CAF, Horwitz EM, Michalski JM, Roof K, Beyer DC, Zhang Q, Sandler HM. Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621. Cancer. 2017 Jul 1; 123 (13):2489-2496 Epub 2017 Mar 21
    View PubMed
  191. Odo U, Vasudevamurthy AK, Sartor O. Acute Promyelocytic Leukemia After Treatment of Metastatic Castration-Resistant Prostate Cancer With Radium-223. Clin Genitourin Cancer. 2017 Jun; 15 (3):e501-e502 Epub 2016 Dec 29
    View PubMed
  192. Buyyounouski MK, Choyke PL, McKenney JK, Sartor O, Sandler HM, Amin MB, Kattan MW, Lin DW. Prostate cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017 May 6; 67 (3):245-253 Epub 2017 Feb 21
    View PubMed
  193. Crawford ED, Petrylak D, Sartor O. Navigating the evolving therapeutic landscape in advanced prostate cancer. Urol Oncol. 2017 May; 35S:S1-S13 Epub 2017 Mar 07
    View PubMed
  194. Sartor O, Coleman RE, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Vogelzang NJ, Bruland O, Kobina S, Wilhelm S, Xu L, Shan M, Kattan MW, Parker C. An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223. Ann Oncol. 2017 May 1; 28 (5):1090-1097
    View PubMed
  195. McKay RR, Jacobus S, Fiorillo M, Ledet EM, Cotogna PM, Steinberger AE, Jacene HA, Sartor O, Taplin ME. Radium-223 Use in Clinical Practice and Variables Associated With Completion of Therapy. Clin Genitourin Cancer. 2017 Apr; 15 (2):e289-e298 Epub 2016 Aug 20
    View PubMed
  196. Bertagnolli MM, Sartor O, Chabner BA, Rothenberg ML, Khozin S, Hugh-Jones C, Reese DM, Murphy MJ. Advantages of a Truly Open-Access Data-Sharing Model. N Engl J Med. 2017 Mar 23; 376 (12):1178-1181
    View PubMed
  197. Shipley WU, Seiferheld W, Lukka HR, Major PP, Heney NM, Grignon DJ, Sartor O, Patel MP, Bahary JP, Zietman AL, Pisansky TM, Zeitzer KL, Lawton CA, Feng FY, Lovett RD, Balogh AG, Souhami L, Rosenthal SA, Kerlin KJ, Dignam JJ, Pugh SL, Sandler HM, NRG Oncology RTOG. Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer. N Engl J Med. 2017 Feb 02; 376(5):417-428.
    View PubMed
  198. Steinberger AE, Cotogno P, Ledet EM, Lewis B, Sartor O. Exceptional Duration of Radium-223 in Prostate Cancer With a BRCA2 Mutation. Clin Genitourin Cancer. 2017 Feb; 15 (1):e69-e71 Epub 2016 Sept 17
    View PubMed
  199. Vasudevamurthy AK, Ledet E, Garvey C, Lewis BE, Sartor O. Estrogen-Mediated Activation of H875Y Androgen Receptor Mutation in a Prostate Cancer Patient. Clin Genitourin Cancer. 2017 Feb; 15 (1):e111-e113 Epub 2016 July 22
    View PubMed
  200. Vogelzang NJ, Coleman RE, Michalski JM, Nilsson S, O'Sullivan JM, Parker C, Widmark A, Thuresson M, Xu L, Germino J, Sartor O. Hematologic Safety of Radium-223 Dichloride: Baseline Prognostic Factors Associated With Myelosuppression in the ALSYMPCA Trial. Clin Genitourin Cancer. 2017 Feb; 15 (1):42-52.e8 Epub 2016 Aug 08
    View PubMed
  201. Qu F, Xie W, Nakabayashi M, Zhang H, Jeong SH, Wang X, Komura K, Sweeney CJ, Sartor O, Lee GM, Kantoff PW. Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer. Clin Cancer Res. 2017 Feb 1; 23 (3):726-734 Epub 2016 Aug 03
    View PubMed
  202. Bennett CL, Sartor OA, Armitage JO, Kantarjian H. Biosimilar and generic cancer drugs unlikely to bend cost curve in the USA. Lancet Oncol. 2017 Jan; 18 (1):22-23
    View PubMed
  203. Zhan Y, Zhang G, Wang X, Qi Y, Bai S, Li D, Ma T, Sartor O, Flemington EK, Zhang H, Lee P, Dong Y. Interplay between Cytoplasmic and Nuclear Androgen Receptor Splice Variants Mediates Castration Resistance. Mol Cancer Res. 2017 Jan; 15 (1):59-68 Epub 2016 Sept 26
    View PubMed
  204. Hicks C, Ramani R, Sartor O, Bhalla R, Miele L, Dlamini Z, Gumede N. An Integrative Genomics Approach for Associating Genome-Wide Association Studies Information With Localized and Metastatic Prostate Cancer Phenotypes. Biomark Insights. 2017; 12:1177271917695810 Epub 2017 Mar 16
    View PubMed
  205. Parker C, Zhan L, Cislo P, Reuning-Scherer J, Vogelzang NJ, Nilsson S, Sartor O, O'Sullivan JM, Coleman RE. Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial. Eur J Cancer. 2017 Jan; 71:1-6 Epub 2016 Dec 06
    View PubMed
  206. Guinney J, Wang T, Laajala TD, Winner KK, Bare JC, Neto EC, Khan SA, Peddinti G, Airola A, Pahikkala T, Mirtti T, Yu T, Bot BM, Shen L, Abdallah K, Norman T, Friend S, Stolovitzky G, Soule H, Sweeney CJ, Ryan CJ, Scher HI, Sartor O, Xie Y, Aittokallio T, Zhou FL, Costello JC, Prostate Cancer Challenge DREAM Community. Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data. Lancet Oncol. 2017 Jan; 18 (1):132-142 Epub 2016 Nov 16
    View PubMed
  207. Sartor O, Lewis B. Beyond Just Androgen Deprivation Therapy: Novel Therapies Combined With Radiation. Semin Radiat Oncol. 2017 Jan; 27 (1):87-93 Epub 2016 Aug 26
    View PubMed
  208. Liu X, Ledet E, Li D, Dotiwala A, Steinberger A, Feibus A, Li J, Qi Y, Silberstein J, Lee B, Dong Y, Sartor O, Zhang H. A Whole Blood Assay for AR-V7 and AR(v567es) in Patients with Prostate Cancer. J Urol. 2016 Dec; 196 (6):1758-1763 Epub 2016 July 20
    View PubMed
  209. Parker C, Finkelstein SE, Michalski JM, O'Sullivan JM, Bruland O, Vogelzang NJ, Coleman RE, Nilsson S, Sartor O, Li R, Seger MA, Bottomley D. Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial. Eur Urol. 2016 Nov; 70 (5):875-883 Epub 2016 June 22
    View PubMed
  210. Yang YT, Nagai S, Chen BK, Qureshi ZP, Lebby AA, Kessler S, Georgantopoulos P, Raisch DW, Sartor O, Hermanson T, Kane RC, Hrushesky WJ, Riente JJ, Norris LB, Bobolts LR, Armitage JO, Bennett CL. Generic oncology drugs: are they all safe? Lancet Oncol. 2016 Nov; 17 (11):e493-e501
    View PubMed
  211. Sartor O. Prostate cancer: What is the optimal treatment sequence for mCRPC? Nat Rev Urol. 2016 Oct 31; 13 (11):639-640
    View PubMed
  212. Feibus AH, Sartor O, Moparty K, Chagin K, Kattan MW, Ledet E, Levy J, Lee B, Thomas R, Silberstein JL. Clinical Use of PCA3 and TMPRSS2:ERG Urinary Biomarkers in African-American Men Undergoing Prostate Biopsy. J Urol. 2016 Oct; 196 (4):1053-60 Epub 2016 Apr 29
    View PubMed
  213. Sartor O. Isotope Therapy for Castrate-Resistant Prostate Cancer: Unique Sequencing and Combinations. Cancer J. 2016 Sep/Oct; 22 (5):342-346
    View PubMed
  214. Feibus AH, Levy J, McCaslin IR, Doucet ME, Sholl AB, Moparty K, Thomas R, Sartor O, Silberstein JL. Racial variation in prostate needle biopsy templates directed anterior to the peripheral zone. Urol Oncol. 2016 Aug; 34 (8):336.e1-6 Epub 2016 May 05
    View PubMed
  215. Sartor O, Hoskin P, Coleman RE, Nilsson S, Vogelzang NJ, Petrenciuc O, Staudacher K, Thuresson M, Parker C. Chemotherapy following radium-223 dichloride treatment in ALSYMPCA. Prostate. 2016 Jul; 76 (10):905-16 Epub 2016 Mar 23
    View PubMed
  216. Nilsson S, Cislo P, Sartor O, Vogelzang NJ, Coleman RE, O'Sullivan JM, Reuning-Scherer J, Shan M, Zhan L, Parker C. Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study. Ann Oncol. 2016 May; 27 (5):868-74 Epub 2016 Feb 23
    View PubMed
  217. Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN, Corn PG, de Bono JS, Dreicer R, George DJ, Heath EI, Hussain M, Kelly WK, Liu G, Logothetis C, Nanus D, Stein MN, Rathkopf DE, Slovin SF, Ryan CJ, Sartor O, Small EJ, Smith MR, Sternberg CN, Taplin ME, Wilding G, Nelson PS, Schwartz LH, Halabi S, Kantoff PW, Armstrong AJ, Prostate Cancer Clinical Trials Working Group 3. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016 Apr 20; 34(12):1402-18. Epub 2016 Feb 22.
    View PubMed
  218. Stolten M, Ledet E, Dotiwala A, Luk E, Sartor O. Alternative Digit Ratios and Their Relationship to Prostate Cancer. Clin Genitourin Cancer. 2016 Apr; 14 (2):149-52 Epub 2015 Nov 12
    View PubMed
  219. Ahaghotu C, Tyler R, Sartor O. African American Participation in Oncology Clinical Trials--Focus on Prostate Cancer: Implications, Barriers, and Potential Solutions. Clin Genitourin Cancer. 2016 Apr; 14 (2):105-16 Epub 2015 Dec 17
    View PubMed
  220. Steinberger AE, Ledet EM, Luk E, Cotogno P, Stolten M, Desmond D, Feibus A, Silberstein J, Sartor O. Characterizations of Clinical and Therapeutic Histories for Men With Prostate Cancer-Specific Mortality. Clin Genitourin Cancer. 2016 Apr; 14 (2):139-48 Epub 2015 Nov 11
    View PubMed
  221. Liu S, Zhang Q, Chen C, Ge D, Qu Y, Chen R, Fan YM, Li N, Tang WW, Zhang W, Zhang K, Wang AR, Rowan BG, Hill SM, Sartor O, Abdel-Mageed AB, Myers L, Lin Q, You Z. Hyperinsulinemia enhances interleukin-17-induced inflammation to promote prostate cancer development in obese mice through inhibiting glycogen synthase kinase 3-mediated phosphorylation and degradation of interleukin-17 receptor. Oncotarget. 2016 Mar 22; 7 (12):13651-66
    View PubMed
  222. Meisel A, von Felten S, Vogt DR, Liewen H, de Wit R, de Bono J, Sartor O, Stenner-Liewen F. Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial. Eur J Cancer. 2016 Mar; 56:93-100 Epub 2016 Jan 30
    View PubMed
  223. Shore ND, Crawford ED, Higano CS, Sartor O. Advancing Treatment Strategies in Metastatic Castration-resistant Prostate Cancer: The Urologists Role Urology. 2016.
  224. Kaur K, Fayad R, Saxena A, Frizzell N, Chanda A, Das S, Chatterjee S, Hegde S, Baliga MS, Ponemone V, Rorro M, Greene J, Elraheb Y, Redd AJ, Bian J, Restaino J, Norris LB, Qureshi ZP, Love BL, Brookstaver B, Georgantopoulos P, Sartor O, Raisch DW, Rao G, Lu K, Ray P, Hrusheshky W, Schulz R, Ablin R, Noxon V, Bennett CL, Southern Network on Adverse Reactions (SONAR) project. Fluoroquinolone-related neuropsychiatric and mitochondrial toxicity: a collaborative investigation by scientists and members of a social network. J Community Support Oncol. 2016 Feb; 14 (2):54-65
    View PubMed
  225. McNeel DG, Bander NH, Beer TM, Drake CG, Fong L, Harrelson S, Kantoff PW, Madan RA, Oh WK, Peace DJ, Petrylak DP, Porterfield H, Sartor O, Shore ND, Slovin SF, Stein MN, Vieweg J, Gulley JL. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma. J Immunother Cancer. 2016; 4:92 Epub 2016 Dec 20
    View PubMed
  226. Sweeney C, Nakabayashi M, Regan M, Xie W, Hayes J, Keating N, Li S, Philipson T, Buyse M, Halabi S, Kantoff P, Sartor AO, Soule H, Mahal B, ICECaP Working Group. The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP). J Natl Cancer Inst. 2015 Dec; 107 (12):djv261 Epub 2015 Sept 25
    View PubMed
  227. Gartrell BA, Coleman R, Efstathiou E, Fizazi K, Logothetis CJ, Smith MR, Sonpavde G, Sartor O, Saad F. Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options. Eur Urol. 2015 Nov; 68 (5):850-8 Epub 2015 July 04
    View PubMed
  228. Rosenthal SA, Hunt D, Sartor AO, Pienta KJ, Gomella L, Grignon D, Rajan R, Kerlin KJ, Jones CU, Dobelbower M, Shipley WU, Zeitzer K, Hamstra DA, Donavanik V, Rotman M, Hartford AC, Michalski J, Seider M, Kim H, Kuban DA, Moughan J, Sandler H. A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902. Int J Radiat Oncol Biol Phys. 2015 Oct 1; 93 (2):294-302 Epub 2015 July 21
    View PubMed
  229. Zhang G, Liu X, Li J, Ledet E, Alvarez X, Qi Y, Fu X, Sartor O, Dong Y, Zhang H. Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agents. Oncotarget. 2015 Sep 15; 6 (27):23358-71
    View PubMed
  230. Xu D, Zhan Y, Qi Y, Cao B, Bai S, Xu W, Gambhir SS, Lee P, Sartor O, Flemington EK, Zhang H, Hu CD, Dong Y. Androgen Receptor Splice Variants Dimerize to Transactivate Target Genes. Cancer Res. 2015 Sep 1; 75 (17):3663-71 Epub 2015 June 09
    View PubMed
  231. Omlin A, Sartor O, Rothermundt C, Cathomas R, De Bono JS, Shen L, Su Z, Gillessen S. Analysis of Side Effect Profile of Alopecia, Nail Changes, Peripheral Neuropathy, and Dysgeusia in Prostate Cancer Patients Treated With Docetaxel and Cabazitaxel. Clin Genitourin Cancer. 2015 Aug; 13 (4):e205-e208 Epub 2015 Jan 30
    View PubMed
  232. Chu FM, Sartor O, Gomella L, Rudo T, Somerville MC, Hereghty B, Manyak MJ. A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer. Eur J Cancer. 2015 Aug; 51 (12):1555-69 Epub 2015 June 02
    View PubMed
  233. Lewis B, Chalhoub E, Chalouhy C, Sartor O. Radium-223 in Bone-Metastatic Prostate Cancer: Current Data and Future Prospects. Oncology (Williston Park). 2015 Jul; 29 (7):483-8
    View PubMed
  234. Humm JL, Sartor O, Parker C, Bruland OS, Macklis R. Radium-223 in the treatment of osteoblastic metastases: a critical clinical review. Int J Radiat Oncol Biol Phys. 2015 Apr 1; 91 (5):898-906
    View PubMed
  235. Sartor O, Flood E, Beusterien K, Park J, Webb I, MacLean D, Wong BJ, Mark Lin H. Health-related quality of life in advanced prostate cancer and its treatments: biochemical failure and metastatic disease populations. Clin Genitourin Cancer. 2015 Apr; 13 (2):101-12 Epub 2014 Aug 19
    View PubMed
  236. Lorente D, Mateo J, Templeton AJ, Zafeiriou Z, Bianchini D, Ferraldeschi R, Bahl A, Shen L, Su Z, Sartor O, de Bono JS. Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use. Ann Oncol. 2015 Apr; 26 (4):750-755 Epub 2014 Dec 23
    View PubMed
  237. Sartor O, Halabi S. Independent data monitoring committees: an update and overview. Urol Oncol. 2015 Mar; 33 (3):143-8 Epub 2015 Jan 24
    View PubMed
  238. Mahal BA, Chen MH, Bennett CL, Kattan MW, Sartor O, Stein K, D'Amico AV, Nguyen PL. The association between race and treatment regret among men with recurrent prostate cancer. Prostate Cancer Prostatic Dis. 2015 Mar; 18 (1):38-42 Epub 2014 Oct 28
    View PubMed
  239. Basch E, Autio KA, Smith MR, Bennett AV, Weitzman AL, Scheffold C, Sweeney C, Rathkopf DE, Smith DC, George DJ, Higano CS, Harzstark AL, Sartor AO, Gordon MS, Vogelzang NJ, de Bono JS, Haas NB, Corn PG, Schimmoller F, Scher HI. Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort. Eur Urol. 2015 Feb; 67 (2):310-8 Epub 2014 Feb 20
    View PubMed
  240. Crawford ED, Moul JW, Sartor O, Shore ND. Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl. Expert Opin Drug Metab Toxicol. 2015; 11 (9):1465-74
    View PubMed
  241. Powers MK, Sartor O, Lee BR. Neoadjuvant Tyrosine Kinase Downstaging of T2 Renal Cell Carcinoma in Solitary Kidney Before Robotic Partial Nephrectomy. J Endourol Case Rep. 2015; 1 (1):47-9 Epub 2015 Nov 01
    View PubMed
  242. Silberstein JL, Feibus AH, Maddox MM, Abdel-Mageed AB, Moparty K, Thomas R, Sartor O. Active surveillance of prostate cancer in African American men. Urology. 2014 Dec; 84 (6):1255-61 Epub 2014 Oct 03
    View PubMed
  243. Bennett CL, Chen B, Hermanson T, Wyatt MD, Schulz RM, Georgantopoulos P, Kessler S, Raisch DW, Qureshi ZP, Lu ZK, Love BL, Noxon V, Bobolts L, Armitage M, Bian J, Ray P, Ablin RJ, Hrushesky WJ, Macdougall IC, Sartor O, Armitage JO. Regulatory and clinical considerations for biosimilar oncology drugs. Lancet Oncol. 2014 Dec; 15 (13):e594-e605 Epub 2014 Nov 24
    View PubMed
  244. Hoskin P, Sartor O, O'Sullivan JM, Johannessen DC, Helle SI, Logue J, Bottomley D, Nilsson S, Vogelzang NJ, Fang F, Wahba M, Aksnes AK, Parker C. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol. 2014 Nov; 15 (12):1397-406 Epub 2014 Oct 17
    View PubMed
  245. Smith MR, Sweeney CJ, Corn PG, Rathkopf DE, Smith DC, Hussain M, George DJ, Higano CS, Harzstark AL, Sartor AO, Vogelzang NJ, Gordon MS, de Bono JS, Haas NB, Logothetis CJ, Elfiky A, Scheffold C, Laird AD, Schimmoller F, Basch EM, Scher HI. Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study. J Clin Oncol. 2014 Oct 20; 32 (30):3391-9 Epub 2014 Sept 15
    View PubMed
  246. Ryan CJ, Saylor PJ, Everly JJ, Sartor O. Bone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new data. Oncologist. 2014 Oct; 19 (10):1012-8 Epub 2014 Sept 17
    View PubMed
  247. Pal SK, Sartor O. Prostate cancer: the best fit for enzalutamide in metastatic prostate cancer. Nat Rev Clin Oncol. 2014 Sep; 11 (9):504-6 Epub 2014 July 29
    View PubMed
  248. Schutz FA, Buzaid AC, Sartor O. Taxanes in the management of metastatic castration-resistant prostate cancer: efficacy and management of toxicity. Crit Rev Oncol Hematol. 2014 Sep; 91 (3):248-56 Epub 2014 Feb 15
    View PubMed
  249. Carson KR, Newsome SD, Kim EJ, Wagner-Johnston ND, von Geldern G, Moskowitz CH, Moskowitz AJ, Rook AH, Jalan P, Loren AW, Landsburg D, Coyne T, Tsai D, Raisch DW, Norris LB, Bookstaver PB, Sartor O, Bennett CL. Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project. Cancer. 2014 Aug 15; 120 (16):2464-71 Epub 2014 Apr 25
    View PubMed
  250. Sartor O, Silberstein J. Prostate cancer: primary ADT monotherapy not suitable for localized disease. Nat Rev Urol. 2014 Jun; 11 (6):309-10 Epub 2014 May 27
    View PubMed
  251. Sartor O, Coleman R, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fossa SD, Chodacki A, Wiechno P, Logue J, Widmark A, Johannessen DC, Hoskin P, James ND, Solberg A, Syndikus I, Vogelzang NJ, O'Bryan-Tear CG, Shan M, Bruland OS, Parker C. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol. 2014 Jun; 15 (7):738-46 Epub 2014 May 13
    View PubMed
  252. Jarow JP, Thompson IM, Kluetz PG, Baxley J, Sridhara R, Scardino P, Carroll P, Albertsen P, Carter HB, Brawley O, Sartor O, Sandler H, Kiefert JJ, Morton RA Jr. Drug and device development for localized prostate cancer: report of a Food and Drug Administration/American Urological Association public workshop. Urology. 2014 May; 83 (5):975-8 Epub 2014 Mar 22
    View PubMed
  253. Vuong W, Sartor O, Pal SK. Radium-223 in metastatic castration resistant prostate cancer. Asian J Androl. 2014 May-Jun; 16 (3):348-53
    View PubMed
  254. Sartor O, Gillessen S. Treatment sequencing in metastatic castrate-resistant prostate cancer. Asian J Androl. 2014 May-Jun; 16 (3):426-31
    View PubMed
  255. Egan A, Dong Y, Zhang H, Qi Y, Balk SP, Sartor O. Castration-resistant prostate cancer: adaptive responses in the androgen axis. Cancer Treat Rev. 2014 Apr; 40 (3):426-33 Epub 2013 Sept 14
    View PubMed
  256. Abd Elmageed ZY, Yang Y, Thomas R, Ranjan M, Mondal D, Moroz K, Fang Z, Rezk BM, Moparty K, Sikka SC, Sartor O, Abdel-Mageed AB. Neoplastic reprogramming of patient-derived adipose stem cells by prostate cancer cell-associated exosomes. Stem Cells. 2014 Apr; 32 (4):983-97
    View PubMed
  257. Cao B, Qi Y, Zhang G, Xu D, Zhan Y, Alvarez X, Guo Z, Fu X, Plymate SR, Sartor O, Zhang H, Dong Y. Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy. Oncotarget. 2014 Mar 30; 5 (6):1646-56
    View PubMed
  258. Murphy DG, Ahlering T, Catalona WJ, Crowe H, Crowe J, Clarke N, Cooperberg M, Gillatt D, Gleave M, Loeb S, Roobol M, Sartor O, Pickles T, Wootten A, Walsh PC, Costello AJ. The Melbourne Consensus Statement on the early detection of prostate cancer. BJU Int. 2014 Feb; 113 (2):186-8
    View PubMed
  259. Sridhar SS, Freedland SJ, Gleave ME, Higano C, Mulders P, Parker C, Sartor O, Saad F. Castration-resistant prostate cancer: from new pathophysiology to new treatment. Eur Urol. 2014 Feb; 65 (2):289-99 Epub 2013 Aug 11
    View PubMed
  260. Myers CE, Gatalica Z, Spinelli A, Castro M, Linden E, Sartor O, Sargent M. Metastatic Cancer of Cowper's Gland: A Rare Cancer Managed Successfully by Molecular Profiling. Case Rep Oncol. 2014 Jan; 7 (1):52-7 Epub 2014 Jan 16
    View PubMed
  261. Gomella LG, Oliver Sartor A. The current role and limitations of surrogate endpoints in advanced prostate cancer. Urol Oncol. 2014 Jan; 32 (1):28.e1-9 Epub 2013 Feb 20
    View PubMed
  262. Halabi S, Lin CY, Small EJ, Armstrong AJ, Kaplan EB, Petrylak D, Sternberg CN, Shen L, Oudard S, de Bono J, Sartor O. Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. J Natl Cancer Inst. 2013 Nov 20; 105 (22):1729-37 Epub 2013 Oct 17
    View PubMed
  263. Sciarra A, Abrahamsson PA, Brausi M, Galsky M, Mottet N, Sartor O, Tammela TL, Calais da Silva F. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials. Eur Urol. 2013 Nov; 64 (5):722-30 Epub 2013 Apr 19
    View PubMed
  264. Halabi S, Armstrong AJ, Sartor O, de Bono J, Kaplan E, Lin CY, Solomon NC, Small EJ. Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy. J Clin Oncol. 2013 Nov 1; 31 (31):3944-50 Epub 2013 Oct 07
    View PubMed
  265. Zhan Y, Cao B, Qi Y, Liu S, Zhang Q, Zhou W, Xu D, Lu H, Sartor O, Kong W, Zhang H, Dong Y. Methylselenol prodrug enhances MDV3100 efficacy for treatment of castration-resistant prostate cancer. Int J Cancer. 2013 Nov; 133 (9):2225-33 Epub 2013 May 09
    View PubMed
  266. Bahl A, Oudard S, Tombal B, Ozguroglu M, Hansen S, Kocak I, Gravis G, Devin J, Shen L, de Bono JS, Sartor AO, TROPIC Investigators. Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann Oncol. 2013 Sep; 24 (9):2402-8 Epub 2013 May 30
    View PubMed
  267. Silberstein JL, Pal SK, Lewis B, Sartor O. Current clinical challenges in prostate cancer. Transl Androl Urol. 2013 Sep; 2 (3):122-36
    View PubMed
  268. Valicenti RK, Thompson I Jr, Albertsen P, Davis BJ, Goldenberg SL, Wolf JS, Sartor O, Klein E, Hahn C, Michalski J, Roach M 3rd, Faraday MM, American Society for Radiation Oncology/American Urological Association. Adjuvant and salvage radiation therapy after prostatectomy: American Society for Radiation Oncology/American Urological Association guidelines. Int J Radiat Oncol Biol Phys. 2013 Aug 01; 86(5):822-8.
    View PubMed
  269. Thompson IM, Valicenti RK, Albertsen P, Davis BJ, Goldenberg SL, Hahn C, Klein E, Michalski J, Roach M, Sartor O, Wolf JS Jr, Faraday MM. Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline. J Urol. 2013 Aug; 190(2):441-9. Epub 2013 May 21.
    View PubMed
  270. Brown M, Cox R, Fletcher C, Foley M, Graham J, Jenkins C, Robinson A, Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fossa SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franzen L, Coleman R, Vogelzang NJ, O'Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland OS, Sartor O, ALSYMPCA Investigators. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013 Jul 18; 369 (3):213-23
    View PubMed
  271. Ledet EM, Hu X, Sartor O, Rayford W, Li M, Mandal D. Characterization of germline copy number variation in high-risk African American families with prostate cancer. Prostate. 2013 May; 73 (6):614-23 Epub 2012 Oct 11
    View PubMed
  272. Kattan MW, Yu C, Stephenson AJ, Sartor O, Tombal B. Clinicians versus nomogram: predicting future technetium-99m bone scan positivity in patients with rising prostate-specific antigen after radical prostatectomy for prostate cancer. Urology. 2013 May; 81 (5):956-61 Epub 2013 Jan 30
    View PubMed
  273. Lu K, Chen B, Qureshi Z, Xirasagar S, Sartor O, Bennett C. Health care fraud 2006 to 2011 Value Health. 2013; 16(3):198.
  274. Pal SK, Stein CA, Sartor O. Enzalutamide for the treatment of prostate cancer. Expert Opin Pharmacother. 2013 Apr; 14 (5):679-85 Epub 2013 Feb 27
    View PubMed
  275. Cao B, Liu X, Li J, Liu S, Qi Y, Xiong Z, Zhang A, Wiese T, Fu X, Gu J, Rennie PS, Sartor O, Lee BR, Ip C, Zhao L, Zhang H, Dong Y. 20(S)-protopanaxadiol-aglycone downregulation of the full-length and splice variants of androgen receptor. Int J Cancer. 2013 Mar 15; 132 (6):1277-87 Epub 2012 Aug 20
    View PubMed
  276. Waters M, Rebholz CM, Wood B, Kuske A, McIntyre M, Sartor O. Second to fourth digit ratio and prostate cancer severity. Prostate Cancer Prostatic Dis. 2013 Mar; 16 (1):107-10 Epub 2012 Nov 13
    View PubMed
  277. Trost LW, Serefoglu E, Gokce A, Linder BJ, Sartor AO, Hellstrom WJ. Androgen deprivation therapy impact on quality of life and cardiovascular health, monitoring therapeutic replacement. J Sex Med. 2013 Feb; 10 Suppl 1:84-101.
    View PubMed
  278. Sartor O, Hoskin P, Bruland OS. Targeted radio-nuclide therapy of skeletal metastases. Cancer Treat Rev. 2013 Feb; 39 (1):18-26 Epub 2012 Apr 24
    View PubMed
  279. Parekh A, Graham PL, D'Amico AV, Nguyen PL, Chen MH, Hoffman KE, Choueiri TK, Hu JC, Bennett CL, Kattan MW, Sartor O, Stein K. Reply Urology. 2013; 81(1):134-135.
  280. Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, Kuban DA, Sartor AO, Stanford JL, Zietman A, Carroll P, American Urological Association. Prostate specific antigen best practice statement: 2009 update. J Urol. 2013 Jan; 189 (1 Suppl):S2-S11
    View PubMed
  281. Zhang H, Zhan Y, Liu X, Qi Y, Zhang G, Sartor O, Dong Y. Splicing variants of androgen receptor in prostate cancer. Am J Clin Exp Urol. 2013; 1 (1):18-24 Epub 2013 Dec 25
    View PubMed
  282. Sartor O, Eisenberger M, Kattan MW, Tombal B, Lecouvet F. Unmet needs in the prediction and detection of metastases in prostate cancer. Oncologist. 2013; 18 (5):549-57 Epub 2013 May 06
    View PubMed
  283. Sartor O, Pal SK. Abiraterone and its place in the treatment of metastatic CRPC. Nat Rev Clin Oncol. 2013 Jan; 10 (1):6-8 Epub 2012 Nov 13
    View PubMed
  284. Parekh A, Chen MH, Hoffman KE, Choueiri TK, Hu JC, Bennett CL, Kattan MW, Sartor O, Stein K, Graham PL, D'Amico AV, Nguyen PL. Reduced penile size and treatment regret in men with recurrent prostate cancer after surgery, radiotherapy plus androgen deprivation, or radiotherapy alone. Urology. 2013 Jan; 81 (1):130-4
    View PubMed
  285. Liu J, Shi L, Sartor O, Culbertson R. Androgen-deprivation therapy versus radical prostatectomy as monotherapy among clinically localized prostate cancer patients. Onco Targets Ther. 2013; 6:725-32 Epub 2013 June 17
    View PubMed
  286. Bennett CL, Starko KM, Thomsen HS, Cowper S, Sartor O, Macdougall IC, Qureshi ZP, Bookstaver PB, Miller AD, Norris LB, Xirasagar S, Trenery A, Lopez I, Kahn A, Murday A, Luminari S, Cournoyer D, Locatelli F, Ray P, Mattison DR. Linking drugs to obscure illnesses: lessons from pure red cell aplasia, nephrogenic systemic fibrosis, and Reye's syndrome. a report from the Southern Network on Adverse Reactions (SONAR). J Gen Intern Med. 2012 Dec; 27 (12):1697-703 Epub 2012 June 13
    View PubMed
  287. Colli J, Sartor O, Grossman L, Lee BR. Underutilization of partial nephrectomy for stage T1 renal cell carcinoma in the United States, trends from 2000 to 2008. A long way to go. Clin Genitourin Cancer. 2012 Dec; 10 (4):219-24 Epub 2012 June 29
    View PubMed
  288. Pal SK, Lewis B, Sartor O. Management of docetaxel failures in metastatic castrate-resistant prostate cancer. Urol Clin North Am. 2012 Nov; 39(4):583-91. Epub 2012 Aug 29.
    View PubMed
  289. Bennett CL, Spiegel DM, Macdougall IC, Norris L, Qureshi ZP, Sartor O, Lai SY, Tallman MS, Raisch DW, Smith SW, Silver S, Murday AS, Armitage JO, Goldsmith D. A review of safety, efficacy, and utilization of erythropoietin, darbepoetin, and peginesatide for patients with cancer or chronic kidney disease: a report from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost. 2012 Nov; 38 (8):783-96 Epub 2012 Oct 30
    View PubMed
  290. Chen B, Restaino J, Norris L, Xirasagar S, Qureshi ZP, McKoy JM, Lopez IS, Trenery A, Murday A, Kahn A, Mattison DR, Ray P, Sartor O, Bennett CL. A tale of two citizens: a State Attorney General and a hematologist facilitate translation of research into US Food and Drug Administration actions--a SONAR report. J Oncol Pract. 2012 Nov; 8 (6):e158-67 Epub 2012 Aug 14
    View PubMed
  291. Koochekpour S, Majumdar S, Azabdaftari G, Attwood K, Scioneaux R, Subramani D, Manhardt C, Lorusso GD, Willard SS, Thompson H, Shourideh M, Rezaei K, Sartor O, Mohler JL, Vessella RL. Serum glutamate levels correlate with Gleason score and glutamate blockade decreases proliferation, migration, and invasion and induces apoptosis in prostate cancer cells. Clin Cancer Res. 2012 Nov 1; 18 (21):5888-901 Epub 2012 Oct 16
    View PubMed
  292. Sartor AO, Fitzpatrick JM. Urologists and oncologists: adapting to a new treatment paradigm in castration-resistant prostate cancer (CRPC). BJU Int. 2012 Aug; 110 (3):328-35 Epub 2012 June 19
    View PubMed
  293. Grisanzio C, Werner L, Takeda D, Awoyemi BC, Pomerantz MM, Yamada H, Sooriakumaran P, Robinson BD, Leung R, Schinzel AC, Mills I, Ross-Adams H, Neal DE, Kido M, Yamamoto T, Petrozziello G, Stack EC, Lis R, Kantoff PW, Loda M, Sartor O, Egawa S, Tewari AK, Hahn WC, Freedman ML. Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesis. Proc Natl Acad Sci U S A. 2012 Jul 10; 109 (28):11252-7 Epub 2012 June 22
    View PubMed
  294. Nguyen PL, Chen MH, Hoffman KE, Chen RC, Hu JC, Bennett CL, Kattan MW, Sartor O, Stein K, D'Amico AV. Cardiovascular comorbidity and treatment regret in men with recurrent prostate cancer. BJU Int. 2012 Jul; 110 (2):201-5 Epub 2011 Nov 15
    View PubMed
  295. Ledet EM, Sartor O, Rayford W, Bailey-Wilson JE, Mandal DM. Suggestive evidence of linkage identified at chromosomes 12q24 and 2p16 in African American prostate cancer families from Louisiana. Prostate. 2012 Jun 15; 72 (9):938-47 Epub 2011 Oct 05
    View PubMed
  296. Zhang Q, Liu S, Ge D, Zhang Q, Xue Y, Xiong Z, Abdel-Mageed AB, Myers L, Hill SM, Rowan BG, Sartor O, Melamed J, Chen Z, You Z. Interleukin-17 promotes formation and growth of prostate adenocarcinoma in mouse models. Cancer Res. 2012 May 15; 72(10):2589-99. Epub 2012 Mar 28.
    View PubMed
  297. Lewis B, Sartor O. Radiation-based approaches for therapy and palliation of advanced prostate cancer. Curr Opin Urol. 2012 May; 22 (3):183-9
    View PubMed
  298. Sartor O. Experimental therapeutics in prostate cancer: where are we now and where do we need to go. Asian J Androl. 2012 May; 14 (3):421-2 Epub 2012 Apr 23
    View PubMed
  299. Armstrong AJ, Eisenberger MA, Halabi S, Oudard S, Nanus DM, Petrylak DP, Sartor AO, Scher HI. Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. Eur Urol. 2012 Mar; 61 (3):549-59 Epub 2011 Nov 12
    View PubMed
  300. Qureshi ZP, Norris L, Sartor O, McKoy JM, Armstrong J, Raisch DW, Garg V, Stafkey-Mailey D, Bennett CL. Caveat oncologist: clinical findings and consequences of distributing counterfeit erythropoietin in the United States. J Oncol Pract. 2012 Mar; 8 (2):84-90 Epub 2011 Dec 13
    View PubMed
  301. Bennett CL, Qureshi ZP, Sartor AO, Norris LB, Murday A, Xirasagar S, Thomsen HS. Gadolinium-induced nephrogenic systemic fibrosis: the rise and fall of an iatrogenic disease. Clin Kidney J. 2012 Feb; 5 (1):82-88
    View PubMed
  302. Sartor O. State-of-the-Art Management for the Patient with Castration-Resistant Prostate Cancer in 2012. Am Soc Clin Oncol Educ Book. 2012; 289-91
    View PubMed
  303. Sartor O, Maalouf B, Hauck C, Macklis R. Targeted use of Alpha Particles: Current Status in Cancer Therapeutics J Nucl Med Radiat Ther. 2012; 3(4).
  304. Colli J, Sartor O, Thomas R, Lee BR. Does urological cancer mortality increase with low population density of physicians? J Urol. 2011 Dec; 186 (6):2342-6 Epub 2011 Oct 20
    View PubMed
  305. Sartor O, Goeckeler W, Bruland O. Stromal targeted therapy in bone metastatic prostate cancer: promise delivered. Asian J Androl. 2011 Nov; 13 (6):783-4 Epub 2011 Aug 22
    View PubMed
  306. Vasani D, Josephson DY, Carmichael C, Sartor O, Pal SK. Recent advances in the therapy of castration-resistant prostate cancer: the price of progress. Maturitas. 2011 Oct; 70 (2):194-6 Epub 2011 Aug 09
    View PubMed
  307. Qureshi ZP, Sartor O, Xirasagar S, Liu Y, Bennett CL. Pharmaceutical fraud and abuse in the United States, 1996-2010. Arch Intern Med. 2011 Sep 12; 171 (16):1503-6
    View PubMed
  308. Pal SK, Sartor O. Current paradigms and evolving concepts in metastatic castration-resistant prostate cancer. Asian J Androl. 2011 Sep; 13 (5):683-9 Epub 2011 May 23
    View PubMed
  309. Bourgeois DJ 3rd, Kraus S, Maaloof BN, Sartor O. Radiation for bone metastases. Curr Opin Support Palliat Care. 2011 Sep; 5 (3):227-32
    View PubMed
  310. Li J, Cao B, Liu X, Fu X, Xiong Z, Chen L, Sartor O, Dong Y, Zhang H. Berberine suppresses androgen receptor signaling in prostate cancer. Mol Cancer Ther. 2011 Aug; 10 (8):1346-56 Epub 2011 May 25
    View PubMed
  311. Small EJ, Penson DF, Sartor O. The relationship between symptomatology and treatment selection in metastatic castrate-resistant prostate cancer. Clin Adv Hematol Oncol. 2011 Jul; 9 (7 Suppl 13):1-15
    View PubMed
  312. Madan RA, Pal SK, Sartor O, Dahut WL. Overcoming chemotherapy resistance in prostate cancer. Clin Cancer Res. 2011 Jun 15; 17 (12):3892-902
    View PubMed
  313. Sartor O. Randomized studies of PSA screening: an opinion. Asian J Androl. 2011 May; 13 (3):364-5 Epub 2011 Feb 28
    View PubMed
  314. Sartor O. Potential synergistic implications for stromal-targeted radiopharmaceuticals in bone-metastatic prostate cancer. Asian J Androl. 2011 May; 13 (3):366-8 Epub 2011 Apr 18
    View PubMed
  315. Qureshi ZP, Liu Y, Sartor O, Chu YH, Bennett CL. Enforcement actions involving Medicaid fraud and abuse, 1996-2009. Arch Intern Med. 2011 Apr 25; 171 (8):785-7
    View PubMed
  316. Sartor AO. Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space. J Hematol Oncol. 2011 Apr 23; 4:18
    View PubMed
  317. Pal SK, Maalouf BM, Sartor O. Second-Line Chemotherapy for Castration-Resistant Prostate Cancer Demos Medical. 2011; 553-566.
  318. Agarwal N, Sonpavde G, Sartor O. Cabazitaxel for the treatment of castration-resistant prostate cancer. Future Oncol. 2011 Jan; 7 (1):15-24
    View PubMed
  319. Sartor O, Michels RM, Massard C, de Bono JS. Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting. Oncologist. 2011; 16 (11):1487-97 Epub 2011 Nov 02
    View PubMed
  320. Pal SK, Twardowski P, Sartor O. Critical appraisal of cabazitaxel in the management of advanced prostate cancer. Clin Interv Aging. 2010 Dec 3; 5:395-402 Epub 2010 Dec 03
    View PubMed
  321. Sartor O, Halstead M, Katz L. Improving outcomes with recent advances in chemotherapy for castrate-resistant prostate cancer. Clin Genitourin Cancer. 2010 Dec 1; 8 (1):23-8
    View PubMed
  322. Sartor O. Twists and turns on the way to progress in metastatic castrate-resistant prostate cancer. Asian J Androl. 2010 Nov; 12 (6):790-2 Epub 2010 Sept 20
    View PubMed
  323. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO, TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010 Oct 2; 376 (9747):1147-54
    View PubMed
  324. Bennett CL, Lai SY, Henke M, Barnato SE, Armitage JO, Sartor O. Association between pharmaceutical support and basic science research on erythropoiesis-stimulating agents. Arch Intern Med. 2010 Sep 13; 170 (16):1490-8
    View PubMed
  325. Saumya B, Abhijeet Y, Nagpal S, Sartor O. An unusual case of sepsis with both Vibrio vulnificus and Enterococcus casseliflavus. J La State Med Soc. 2010 May-Jun; 162 (3):153-4, 156-7
    View PubMed
  326. Bennett CL, McKoy JM, Henke M, Silver SM, MacDougall IC, Birgegard G, Luminari S, Casadevall N, Schellekens H, Sartor O, Lai SY, Armitage JO. Reassessments of ESAs for cancer treatment in the US and Europe. Oncology (Williston Park). 2010 Mar; 24 (3):260-8
    View PubMed
  327. Baum CE, Ockers SB, English BC, Price DK, Sartor O, Figg WD. Androgen receptor sequence and variations in several common prostate cancer cell lines. Cancer Biol Ther. 2010 Mar 1; 9 (5):383-8 Epub 2010 Mar 08
    View PubMed
  328. Sartor O, McLeod DG, Halabi S, Schellhammer PF, Scardino PT, D'Amico AV, Bennett C, Wei JT, COMPARE Registry Steering Committee. The COMPARE Registry: design and baseline patterns of care for men with biochemical failure after definitive treatment of localized prostate cancer. Urology. 2010 Mar; 75(3):623-9. Epub 2009 Jul 08.
    View PubMed
  329. Taplin ME, Regan MM, Ko YJ, Bubley GJ, Duggan SE, Werner L, Beer TM, Ryan CW, Mathew P, Tu SM, Denmeade SR, Oh WK, Sartor O, Mantzoros CS, Rittmaster R, Kantoff PW, Balk SP. Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. Clin Cancer Res. 2009 Nov 15; 15 (22):7099-105 Epub 2009 Nov 03
    View PubMed
  330. Sternberg CN, Petrylak DP, Sartor O, Witjes JA, Demkow T, Ferrero JM, Eymard JC, Falcon S, Calabro F, James N, Bodrogi I, Harper P, Wirth M, Berry W, Petrone ME, McKearn TJ, Noursalehi M, George M, Rozencweig M. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol. 2009 Nov 10; 27 (32):5431-8 Epub 2009 Oct 05
    View PubMed
  331. Roobol MJ, Schroder FH, Crawford ED, Freedland SJ, Sartor AO, Fleshner N, Andriole GL. A framework for the identification of men at increased risk for prostate cancer. J Urol. 2009 Nov; 182 (5):2112-20 Epub 2009 Sept 16
    View PubMed
  332. Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, Kuban DA, Sartor AO, Stanford JL, Zietman A, Carroll P. Prostate specific antigen best practice statement: 2009 update. J Urol. 2009 Nov; 182 (5):2232-41 Epub 2009 Sept 24
    View PubMed
  333. Sartor O, Nakabayashi M, Taplin ME, Ross RW, Kantoff PW, Balk SP, Oh WK. Activity of dutasteride plus ketoconazole in castration-refractory prostate cancer after progression on ketoconazole alone. Clin Genitourin Cancer. 2009 Oct; 7 (3):E90-2
    View PubMed
  334. Sartor O, Gomella LG, Gagnier P, Melich K, Dann R. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design. Can J Urol. 2009 Oct; 16 (5):4806-12
    View PubMed
  335. Richey EA, Lyons EA, Nebeker JR, Shankaran V, McKoy JM, Luu TH, Nonzee N, Trifilio S, Sartor O, Benson AB 3rd, Carson KR, Edwards BJ, Gilchrist-Scott D, Kuzel TM, Raisch DW, Tallman MS, West DP, Hirschfeld S, Grillo-Lopez AJ, Bennett CL. Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs? J Clin Oncol. 2009 Sep 10; 27 (26):4398-405 Epub 2009 July 27
    View PubMed
  336. Zabaleta J, Su LJ, Lin HY, Sierra RA, Hall MC, Sartor AO, Clark PE, Hu JJ, Ochoa AC. Cytokine genetic polymorphisms and prostate cancer aggressiveness. Carcinogenesis. 2009 Aug; 30 (8):1358-62 Epub 2009 May 27
    View PubMed
  337. Dorr DA, Burdon R, West DP, Lagman J, Georgopoulos C, Belknap SM, McKoy JM, Djulbegovic B, Edwards BJ, Weitzman SA, Boyle S, Tallman MS, Talpaz M, Sartor O, Bennett CL. Quality of reporting of serious adverse drug events to an institutional review board: a case study with the novel cancer agent, imatinib mesylate. Clin Cancer Res. 2009 Jun 01; 15(11):3850-5. Epub 2009 May 19.
    View PubMed
  338. Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, Laubach J, Bawn SD, Gordon LI, Winter JN, Furman RR, Vose JM, Zelenetz AD, Mamtani R, Raisch DW, Dorshimer GW, Rosen ST, Muro K, Gottardi-Littell NR, Talley RL, Sartor O, Green D, Major EO, Bennett CL. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009 May 14; 113(20):4834-40. Epub 2009 Mar 05.
    View PubMed
  339. Penney KL, Salinas CA, Pomerantz M, Schumacher FR, Beckwith CA, Lee GS, Oh WK, Sartor O, Ostrander EA, Kurth T, Ma J, Mucci L, Stanford JL, Kantoff PW, Hunter DJ, Stampfer MJ, Freedman ML. Evaluation of 8q24 and 17q risk loci and prostate cancer mortality. Clin Cancer Res. 2009 May 1; 15 (9):3223-30 Epub 2009 Apr 14
    View PubMed
  340. Choueiri TK, Xie W, D'Amico AV, Ross RW, Hu JC, Pomerantz M, Regan MM, Taplin ME, Kantoff PW, Sartor O, Oh WK. Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. Cancer. 2009 Mar 1; 115 (5):981-7
    View PubMed
  341. Figg WD, Hussain MH, Gulley JL, Arlen PM, Aragon-Ching JB, Petrylak DP, Higano CS, Steinberg SM, Chatta GS, Parnes H, Wright JJ, Sartor O, Dahut WL. A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation. J Urol. 2009 Mar; 181 (3):1104-13; discussion 1113 Epub 2009 Jan 23
    View PubMed
  342. Shah SK, Trump DL, Sartor O, Tan W, Wilding GE, Mohler JL. Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapy. J Urol. 2009 Feb; 181(2):621-6. Epub 2008 Dec 16.
    View PubMed
  343. Barrisford GW, Sartor O, Richie JP. Solitary adrenal metastatic lesion in a patient with a history of prostate cancer. Clin Genitourin Cancer. 2009 Jan; 7 (1):64-6
    View PubMed
  344. Penson DF, Rossignol M, Sartor AO, Scardino PT, Abenhaim LL. Prostate cancer: epidemiology and health-related quality of life. Urology. 2008 Dec; 72 (6 Suppl):S3-11
    View PubMed
  345. Sartor AO, Hricak H, Wheeler TM, Coleman J, Penson DF, Carroll PR, Rubin MA, Scardino PT. Evaluating localized prostate cancer and identifying candidates for focal therapy. Urology. 2008 Dec; 72 (6 Suppl):S12-24
    View PubMed
  346. Sartor O. Counseling the Prostate Cancer Patient European Urology Supplements. 2008; 7(13):765-771.
  347. Gulley JL, Aragon-Ching JB, Steinberg SM, Hussain MH, Sartor O, Higano CS, Petrylak DP, Chatta GS, Arlen PM, Figg WD, Dahut WL. Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2008 Oct; 180 (4):1432-7; discussion 1437 Epub 2008 Aug 16
    View PubMed
  348. Grothey E, Gibson T, Sartor O, Bukowski R. Highlights from: The 2008 meeting of the American Society of Clinical Oncology; May 30-June 3, 2008; Chicago, IL. Clin Genitourin Cancer. 2008 Sep; 6 (2):65-72
    View PubMed
  349. Bao BY, Chuang BF, Wang Q, Sartor O, Balk SP, Brown M, Kantoff PW, Lee GS. Androgen receptor mediates the expression of UDP-glucuronosyltransferase 2 B15 and B17 genes. Prostate. 2008 Jun 01; 68(8):839-48.
    View PubMed
  350. Arlen PM, Bianco F, Dahut WL, D'Amico A, Figg WD, Freedland SJ, Gulley JL, Kantoff PW, Kattan MW, Lee A, Regan MM, Sartor O, Prostate Specific Antigen Working Group. Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol. 2008 Jun; 179 (6):2181-5; discussion 2185-6 Epub 2008 Apr 18
    View PubMed
  351. Sartor AO, Tangen CM, Hussain MH, Eisenberger MA, Parab M, Fontana JA, Chapman RA, Mills GM, Raghavan D, Crawford ED, Southwest Oncology Group. Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426). Cancer. 2008 Jun; 112 (11):2393-400
    View PubMed
  352. Schmeeckle KD, Yankelevitz D, Kim JW, Sartor O. Increased uptake of 18F-fluorodeoxyglucose due to Mycobacterium avium complex in a solitary pulmonary nodule. J La State Med Soc. 2008 May-Jun; 160 (3):150-2
    View PubMed
  353. Ross RW, Xie W, Regan MM, Pomerantz M, Nakabayashi M, Daskivich TJ, Sartor O, Taplin ME, Kantoff PW, Oh WK. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect. Cancer. 2008 Mar 15; 112(6):1247-53.
    View PubMed
  354. Zabaleta J, Lin HY, Sierra RA, Hall MC, Clark PE, Sartor OA, Hu JJ, Ochoa AC. Interactions of cytokine gene polymorphisms in prostate cancer risk. Carcinogenesis. 2008 Mar; 29 (3):573-8 Epub 2008 Jan 03
    View PubMed
  355. Higano CS, Quick DP, Bushnell D, Sartor O. Safety analysis of repeated high doses of samarium-153 lexidronam in men with hormone-naive prostate cancer metastatic to bone. Clin Genitourin Cancer. 2008 Mar; 6 (1):40-5
    View PubMed
  356. Sartor O. Prostate specific antigen (PSA) may be a poor marker for progression of prostate cancer after treatment with a combination of chemo-hormonal therapies. J La State Med Soc. 2008 Mar-Apr; 160 (2):99-100
    View PubMed
  357. Ross RW, Oh WK, Xie W, Pomerantz M, Nakabayashi M, Sartor O, Taplin ME, Regan MM, Kantoff PW, Freedman M. Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. J Clin Oncol. 2008 Feb 20; 26 (6):842-7
    View PubMed
  358. Garmey EG, Sartor O, Halabi S, Vogelzang NJ. Second-line chemotherapy for advanced hormone-refractory prostate cancer. Clin Adv Hematol Oncol. 2008 Feb; 6(2):118-22, 127-32.
    View PubMed
  359. Nakabayashi M, Sartor O, Jacobus S, Regan MM, McKearn D, Ross RW, Kantoff PW, Taplin ME, Oh WK. Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer. BJU Int. 2008 Feb; 101 (3):308-12
    View PubMed
  360. Schmeeckle KD, Kim JW, Sartor O. Substantial activity of mitoxantrone and paclitaxel in a heavily pre-treated metastatic bladder cancer patient. J La State Med Soc. 2008 Jan-Feb; 160 (1):17-8
    View PubMed
  361. Mandal DM, Sartor O, Halton SL, Mercante DE, Bailey-Wilson JE, Rayford W. Recruitment strategies and comparison of prostate cancer-specific clinical data on African-American and Caucasian males with and without family history. Prostate Cancer Prostatic Dis. 2008; 11 (3):274-9 Epub 2008 Feb 12
    View PubMed
  362. Eggener SE, Scardino PT, Carroll PR, Zelefsky MJ, Sartor O, Hricak H, Wheeler TM, Fine SW, Trachtenberg J, Rubin MA, Ohori M, Kuroiwa K, Rossignol M, Abenhaim L, International Task Force on Prostate Cancer and the Focal Lesion Paradigm. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol. 2007 Dec; 178 (6):2260-7 Epub 2007 Oct 15
    View PubMed
  363. Wu D, Zhau HE, Huang WC, Iqbal S, Habib FK, Sartor O, Cvitanovic L, Marshall FF, Xu Z, Chung LW. cAMP-responsive element-binding protein regulates vascular endothelial growth factor expression: implication in human prostate cancer bone metastasis. Oncogene. 2007 Aug 2; 26 (35):5070-7 Epub 2007 Feb 19
    View PubMed
  364. Sartor O, Reid RH, Bushnell DL, Quick DP, Ell PJ. Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain. Cancer. 2007 Feb 1; 109 (3):637-43
    View PubMed
  365. Sartor O. Eligard 6: A New Form of Treatment for Prostate Cancer European Urology Supplements. 2006; 5(18):905-910.
  366. Saad F, Higano CS, Sartor O, Colombel M, Murray R, Mason MD, Tubaro A, Schulman C. The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panel. Clin Genitourin Cancer. 2006 Mar; 4 (4):257-62
    View PubMed
  367. Crawford ED, Sartor O, Chu F, Perez R, Karlin G, Garrett JS. A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol. 2006 Feb; 175 (2):533-6
    View PubMed
  368. McKoy JM, Lyons EA, Obadina E, Carson K, Pickard AS, Schellhammer P, McLeod D, Boyd CE, McWilliams N, Sartor O, Schumock GT, McCaffery K, Bennett CL. Caveat medicus: consequences of federal investigations of marketing activities of pharmaceutical suppliers of prostate cancer drugs. J Clin Oncol. 2005 Dec 1; 23 (34):8894-905
    View PubMed
  369. Koochekpour S, Zhuang YJ, Beroukhim R, Hsieh CL, Hofer MD, Zhau HE, Hiraiwa M, Pattan DY, Ware JL, Luftig RB, Sandhoff K, Sawyers CL, Pienta KJ, Rubin MA, Vessella RL, Sellers WR, Sartor O. Amplification and overexpression of prosaposin in prostate cancer. Genes Chromosomes Cancer. 2005 Dec; 44 (4):351-64
    View PubMed
  370. Nakabayashi M, Regan MM, Lifsey D, Kantoff PW, Taplin ME, Sartor O, Oh WK. Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer. BJU Int. 2005 Oct; 96 (6):783-6
    View PubMed
  371. Koochekpour S, Sartor O, Hiraiwa M, Lee TJ, Rayford W, Remmel N, Sandhoff K, Minokadeh A, Patten DY. Saposin C stimulates growth and invasion, activates p42/44 and SAPK/JNK signaling pathways of MAPK and upregulates uPA/uPAR expression in prostate cancer and stromal cells. Asian J Androl. 2005 Jun; 7 (2):147-58
    View PubMed
  372. Bennett CL, Nebeker JR, Lyons EA, Samore MH, Feldman MD, McKoy JM, Carson KR, Belknap SM, Trifilio SM, Schumock GT, Yarnold PR, Davidson CJ, Evens AM, Kuzel TM, Parada JP, Cournoyer D, West DP, Sartor O, Tallman MS, Raisch DW. The Research on Adverse Drug Events and Reports (RADAR) project. JAMA. 2005 May 4; 293 (17):2131-40
    View PubMed
  373. Gulley JL, Figg WD, Steinberg SM, Carter J, Sartor O, Higano CS, Petrylak DP, Chatta G, Hussain MH, Dahut WL. A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy. J Urol. 2005 May; 173 (5):1567-71
    View PubMed
  374. Gandhok NK, Looney S, Koochekpour S, Sartor O. Relationships between reverse transcriptase-polymerase chain reaction for prostate specific antigen, survival, and various prognostic laboratory factors in patients with hormone refractory prostate cancer. Urol Oncol. 2005 May-Jun; 23 (3):163-7
    View PubMed
  375. Price N, Sartor O, Hutson T, Mariani S. Role of 5a-reductase inhibitors and selective estrogen receptor modulators as potential chemopreventive agents for prostate cancer. Clin Prostate Cancer. 2005 Mar; 3 (4):211-4
    View PubMed
  376. Reddy GK, Gibson TB, Hutson T, Marianni S, Sartor O. Highlights from the 2005 American Society of Clinical Oncology Prostate Cancer Symposium, Orlando, Florida. Clin Prostate Cancer. 2005 Mar; 3 (4):206-10
    View PubMed
  377. Chang SS, Benson MC, Campbell SC, Crook J, Dreicer R, Evans CP, Hall MC, Higano C, Kelly WK, Sartor O, Smith JA Jr, Society of Urologic Oncology, Shaumberg, Illinois. Society of Urologic Oncology position statement: redefining the management of hormone-refractory prostate carcinoma. Cancer. 2005 Jan 1; 103 (1):11-21
    View PubMed
  378. Figg WD, Franks ME, Venzon D, Duray P, Cox MC, Linehan WM, Van Bingham W, Eastham JA, Reed E, Sartor O. Gleason score and pretreatment prostate-specific antigen in survival among patients with stage D2 prostate cancer. World J Urol. 2004 Dec; 22 (6):425-30 Epub 2004 Dec 08
    View PubMed
  379. Lee TJ, Sartor O, Luftig RB, Koochekpour S. Saposin C promotes survival and prevents apoptosis via PI3K/Akt-dependent pathway in prostate cancer cells. Mol Cancer. 2004 Nov 17; 3:31
    View PubMed
  380. Kyle C, Ewing T, Wu XC, Mercante D, Lifsey D, Meunier C, Jefferson L, Sartor O, Rayford W. Statewide analysis of serum prostate specific antigen levels in Louisiana men without prostate cancer. J La State Med Soc. 2004 Nov-Dec; 156 (6):319-23
    View PubMed
  381. Gandhok N, Sartor O. Unexpected response of hormone-refractory prostate cancer to treatment with an antileukemic chemotherapy regimen. Urology. 2004 Oct; 64 (4):807-9
    View PubMed
  382. Koochekpour S, Sartor O, Lee TJ, Zieske A, Patten DY, Hiraiwa M, Sandhoff K, Remmel N, Minokadeh A. Prosaptide TX14A stimulates growth, migration, and invasion and activates the Raf-MEK-ERK-RSK-Elk-1 signaling pathway in prostate cancer cells. Prostate. 2004 Oct 1; 61 (2):114-23
    View PubMed
  383. Gilligan T, Manola J, Sartor O, Weinrich SP, Moul JW, Kantoff PW. Absence of a correlation of androgen receptor gene CAG repeat length and prostate cancer risk in an African-American population. Clin Prostate Cancer. 2004 Sep; 3 (2):98-103
    View PubMed
  384. Sartor O, Reid RH, Hoskin PJ, Quick DP, Ell PJ, Coleman RE, Kotler JA, Freeman LM, Olivier P, Quadramet 424Sm10/11 Study Group. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology. 2004 May; 63 (5):940-5
    View PubMed
  385. Eisenberger MA, Laufer M, Vogelzang NJ, Sartor O, Thornton D, Neubauer BL, Sinibaldi V, Lieskovsky G, Carducci MA, Zahurak M, Raghavan D. Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible mechanism of action. Urology. 2004 Jan; 63 (1):114-9
    View PubMed
  386. Sartor O. Overview of samarium sm 153 lexidronam in the treatment of painful metastatic bone disease. Rev Urol. 2004; 6 Suppl 10 (Suppl 10):S3-S12
    View PubMed
  387. Ladewski LA, Belknap SM, Nebeker JR, Sartor O, Lyons EA, Kuzel TC, Tallman MS, Raisch DW, Auerbach AR, Schumock GT, Kwaan HC, Bennett CL. Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports project. J Clin Oncol. 2003 Oct 15; 21 (20):3859-66
    View PubMed
  388. Sartor O, Dineen MK, Perez-Marreno R, Chu FM, Carron GJ, Tyler RC. An eight-month clinical study of LA-2575 30.0 mg: a new 4-month, subcutaneous delivery system for leuprolide acetate in the treatment of prostate cancer. Urology. 2003 Aug; 62 (2):319-23
    View PubMed
  389. Sartor O. Radioisotopic treatment of bone pain from metastatic prostate cancer. Curr Oncol Rep. 2003 May; 5 (3):258-62
    View PubMed
  390. Sartor O. Eligard: leuprolide acetate in a novel sustained-release delivery system. Urology. 2003 Feb; 61 (2 Suppl 1):25-31
    View PubMed
  391. Sartor O. Endpoints in prostate cancer clinical trials. Urology. 2002 Sep; 60 (3 Suppl 1):101-7; discussion 107-8
    View PubMed
  392. Carroll PR, Kantoff PW, Balk SP, Brown MA, D'amico AV, George DJ, Grossfeld GD, Johnson CS, Kelly WK, Klotz L, Lee WR, Lubeck DP, Mcleod DG, Oh WK, Pollack A, Sartor O, Smith MR, Hart C, Second International Conference on Newer Approaches to Androgen Deprivation Therapy (ADT) in Prostate Cancer. Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. Urology. 2002 Sep; 60 (3 Suppl 1):1-6
    View PubMed
  393. Bennett CL, Price DK, Kim S, Liu D, Jovanovic BD, Nathan D, Johnson ME, Montgomery JS, Cude K, Brockbank JC, Sartor O, Figg WD. Racial variation in CAG repeat lengths within the androgen receptor gene among prostate cancer patients of lower socioeconomic status. J Clin Oncol. 2002 Sep 1; 20 (17):3599-604
    View PubMed
  394. Kaur M, Reed E, Sartor O, Dahut W, Figg WD. Suramin's development: what did we learn? Invest New Drugs. 2002 May; 20 (2):209-19
    View PubMed
  395. Jani AB, Vaida F, Hanks G, Asbell S, Sartor O, Moul JW, Roach M 3rd, Brachman D, Kalokhe U, Muller-Runkel R, Ray P, Ignacio L, Awan A, Weichselbaum RR, Vijayakumar S. Changing face and different countenances of prostate cancer: racial and geographic differences in prostate-specific antigen (PSA), stage, and grade trends in the PSA era. Int J Cancer. 2001 Dec 20; 96 (6):363-71
    View PubMed
  396. Kucuk O, Fisher E, Moinpour CM, Coleman D, Hussain MH, Sartor AO, Chatta GS, Lowe BA, Eisenberger MA, Crawford ED. Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235). Urology. 2001 Jul; 58 (1):53-8
    View PubMed
  397. Schmitt B, Wilt TJ, Shellhammer PF, DeMasi V, Sartor O, Bennett CL. Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: A systemic review Urology. 2001; 57(4):727-732.
  398. Williams DL, Sartor O, Judice E. Implementation of current Louisiana mammography legislation: a time for review. J La State Med Soc. 2001 Apr; 153 (4):210-4
    View PubMed
  399. Eastham JA, Sartor O, Richey W, Moparty B, Sullivan J. Racial variation in prostate specific antigen in a large cohort of men without prostate cancer. J La State Med Soc. 2001 Apr; 153 (4):184-9
    View PubMed
  400. Shi R, Berkel H, Sartor O. Comparison of utilization of preventive health care services between two racial populations. Ann Epidemiol. 2000 Oct 1; 10 (7):454
    View PubMed
  401. Small EJ, Figlin R, Petrylak D, Vaughn DJ, Sartor O, Horak I, Pincus R, Kremer A, Bowden C. A phase II pilot study of KW-2189 in patients with advanced renal cell carcinoma. Invest New Drugs. 2000 May; 18 (2):193-7
    View PubMed
  402. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Wilding G. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999 Nov; 17 (11):3461-7
    View PubMed
  403. Eastham JA, May R, Robertson JL, Sartor O, Kattan MW. Development of a nomogram that predicts the probability of a positive prostate biopsy in men with an abnormal digital rectal examination and a prostate-specific antigen between 0 and 4 ng/mL. Urology. 1999 Oct; 54 (4):709-13
    View PubMed
  404. Dale W, Sartor O, Davis T, Bennett CL. Understanding barriers to the early detection of prostate cancer among men of lower socioeconomic status The Prostate Journal. 1999; 1(4):179-184.
  405. Sartor O, Eastham JA. Progressive prostate cancer associated with use of megestrol acetate administered for control of hot flashes. South Med J. 1999 Apr; 92 (4):415-6
    View PubMed
  406. Kubricht WS, Kattan MW, Sartor O, Eastham JA. Race is not independently associated with a positive prostate biopsy in men suspected of having prostate cancer Urology. 1999; 53(3).
  407. Sartor O, Zheng Q, Eastham JA. Androgen receptor gene CAG repeat length varies in a race-specific fashion in men without prostate cancer. Urology. 1999 Feb; 53 (2):378-80
    View PubMed
  408. Bennett CL, Ferreira MR, Davis TC, Kaplan J, Weinberger M, Kuzel T, Seday MA, Sartor O. Relation between literacy, race, and stage of presentation among low-income patients with prostate cancer. J Clin Oncol. 1998 Sep; 16 (9):3101-4
    View PubMed
  409. Sartor O, Weinberger M, Moore A, Li A, Figg WD. Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer. Urology. 1998 Aug; 52 (2):252-6
    View PubMed
  410. Horti J, Figg WD, Weinberger B, Kohler D, Sartor O. A phase II study of bromocriptine in patients with androgen-independent prostate cancer. Oncol Rep. 1998 Jul-Aug; 5 (4):893-6
    View PubMed
  411. Eastham JA, May RA, Whatley T, Crow A, Venable DD, Sartor O. Clinical characteristics and biopsy specimen features in African-American and white men without prostate cancer. J Natl Cancer Inst. 1998 May 20; 90 (10):756-60
    View PubMed
  412. Eastham JA, Sartor O. Nilutamide response after flutamide failure in post-orchiectomy progressive prostate cancer. J Urol. 1998 Mar; 159 (3):990
    View PubMed
  413. Feuer JA, Lush RM, Venzon D, Duray P, Tompkins A, Sartor O, Figg WD. Elevated carcinoembryonic antigen in patients with androgen-independent prostate cancer. J Investig Med. 1998 Feb; 46 (2):66-72
    View PubMed
  414. Dawson N, Figg WD, Brawley OW, Bergan R, Cooper MR, Senderowicz A, Headlee D, Steinberg SM, Sutherland M, Patronas N, Sausville E, Linehan WM, Reed E, Sartor O. Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal. Clin Cancer Res. 1998 Jan; 4 (1):37-44
    View PubMed
  415. Williams PB, Eastham JA, Culkin DJ, Mata JA, Venable DD, Sartor O. Influence of hepatic function on serum levels of prostate specific antigen. J Urol. 1997 Nov; 158 (5):1867-9
    View PubMed
  416. Figg WD, Kroog G, Duray P, Walther MM, Patronas N, Sartor O, Reed E. Flutamide withdrawal plus hydrocortisone resulted in clinical complete response in a patient with prostate carcinoma. Cancer. 1997 May 15; 79 (10):1964-8
    View PubMed
  417. Dawson NA, Figg WD, Cooper MR, Sartor O, Bergan RC, Senderowicz AM, Steinberg SM, Tompkins A, Weinberger B, Sausville EA, Reed E, Myers CE. Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer. J Clin Oncol. 1997 Apr; 15 (4):1470-7
    View PubMed
  418. Sartor O, Zheng Q. Determination of CAG repeat length in the androgen-receptor gene using frozen serum. Urology. 1997 Feb; 49 (2):301-4
    View PubMed
  419. Henderson RJ, Eastham JA, Culkin DJ, Kattan MW, Whatley T, Mata J, Venable D, Sartor O. Prostate-specific antigen (PSA) and PSA density: racial differences in men without prostate cancer. J Natl Cancer Inst. 1997 Jan 15; 89 (2):134-8
    View PubMed
  420. Lush RM, Figg WD, Pluda JM, Bitton R, Headlee D, Kohler D, Reed E, Sartor O, Cooper MR. A phase I study of pentosan polysulfate sodium in patients with advanced malignancies. Ann Oncol. 1996 Nov; 7 (9):939-44
    View PubMed
  421. Sartor O, Figg WD. Mifepristone: antineoplastic studies. Clin Obstet Gynecol. 1996 Jun; 39 (2):498-505
    View PubMed
  422. Sartor O, Cutler GB Jr. Mifepristone: treatment of Cushing's syndrome. Clin Obstet Gynecol. 1996 Jun; 39 (2):506-10
    View PubMed
  423. Sartor O. Early detection of prostate cancer in African-American men with an increased familial risk of disease. J La State Med Soc. 1996 Apr; 148 (4):179-85
    View PubMed
  424. Figg WD, Middleman MN, Sartor O. Therapeutic options in patients with hormone-refractory prostate cancer Am J Med. 1996; 100(2):243-244.
  425. Middleman MN, Lush RM, Sartor O, Reed E, Figg WD. Treatment approaches for metastatic cancer of the prostate based on recent molecular evidence. Cancer Treat Rev. 1996 Mar; 22 (2):105-18
    View PubMed
  426. Figg WD, Dawson N, Middleman MN, Brawley O, Lush RM, Senderowicz A, Steinberg SH, Tompkins A, Reed E, Sartor O. Flutamide withdrawal and concomitant initiation of aminoglutethimide in patients with hormone refractory prostate cancer. Acta Oncol. 1996; 35 (6):763-5
    View PubMed
  427. Figg WD, Ammerman K, Patronas N, Steinberg SM, Walls RG, Dawson N, Reed E, Sartor O. Lack of correlation between prostate-specific antigen and the presence of measurable soft tissue metastases in hormone-refractory prostate cancer. Cancer Invest. 1996; 14 (6):513-7
    View PubMed
  428. Bowden CJ, Figg WD, Dawson NA, Sartor O, Bitton RJ, Weinberger MS, Headlee D, Reed E, Myers CE, Cooper MR. A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: toxicity and response. Cancer Chemother Pharmacol. 1996; 39 (1-2):1-8
    View PubMed
  429. Sartor O. Prostate-specific antigen changes before and after administration of an angiogenesis inhibitor (tnp-470). Oncol Rep. 1995 Nov; 2 (6):1101-2
    View PubMed
  430. Middleman MN, Lush RM, Sartor O, Reed E, and Figg WD. Prolonged response to flutamide withdrawal and initiation of aminoglutethimide in a patient with metastatic prostate cancer J Oncol Pharm Practice. 1995; 1(3):45-47.
  431. Dawson NA, Cooper MR, Figg WD, Headlee DJ, Thibault A, Bergan RC, Steinberg SM, Sausville EA, Myers CE, Sartor O. Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables. Cancer. 1995 Aug 1; 76 (3):453-62
    View PubMed
  432. Borner MM, Myers CE, Sartor O, Sei Y, Toko T, Trepel JB, Schneider E. Drug-induced apoptosis is not necessarily dependent on macromolecular synthesis or proliferation in the p53-negative human prostate cancer cell line PC-3. Cancer Res. 1995 May 15; 55 (10):2122-8
    View PubMed
  433. Sartor BM, Sartor O, Flanders KC. Analogous tamoxifen and estrogen effects on transforming growth factor-betas 1 and 2 in the rat uterus. Reprod Toxicol. 1995 May-Jun; 9 (3):225-31
    View PubMed
  434. Figg WD, Thibault A, Cooper MR, Reid R, Headlee D, Dawson N, Kohler DR, Reed E, Sartor O. A phase I study of the somatostatin analogue somatuline in patients with metastatic hormone-refractory prostate cancer. Cancer. 1995 Apr 15; 75 (8):2159-64
    View PubMed
  435. Figg WD, Sartor O, Cooper MR, Thibault A, Bergan RC, Dawson N, Reed E, Myers CE. Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer. Am J Med. 1995 Apr; 98 (4):412-4
    View PubMed
  436. Figg W, McCall N, Reed E, Sartor O. The in-vitro response of 4 antisteroid receptor agents on the hormone-responsive prostate-cancer cell-line lncap. Oncol Rep. 1995 Mar; 2 (2):295-8
    View PubMed
  437. Borner MM, Schneider E, Pirnia F, Sartor O, Trepel JB, Myers CE. The detergent Triton X-100 induces a death pattern in human carcinoma cell lines that resembles cytotoxic lymphocyte-induced apoptosis. FEBS Lett. 1994 Oct 17; 353 (2):129-32
    View PubMed
  438. Figg WD, Cooper MR, Thibault A, Headlee D, Humphrey J, Bergan RC, Reed E, Sartor O. Acute renal toxicity associated with suramin in the treatment of prostate cancer. Cancer. 1994 Sep 1; 74 (5):1612-4
    View PubMed
  439. Bang YJ, Pirnia F, Fang WG, Kang WK, Sartor O, Whitesell L, Ha MJ, Tsokos M, Sheahan MD, Nguyen P, Niklinski WT, Myers CE, Trepel JB. Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP. Proc Natl Acad Sci U S A. 1994 Jun 7; 91 (12):5330-4
    View PubMed
  440. Figg WD, Walls RG, Cooper MR, Thibault A, Sartor O, McCall NA, Myers CE, Samid D. In vitro antitumor effect of hydroxyurea on hormone-refractory prostate cancer cells and its potentiation by phenylbutyrate. Anticancer Drugs. 1994 Jun; 5 (3):336-42
    View PubMed
  441. Figg WD, Thibault A, Sartor AO, Mays D, Headlee D, Calis KA, Cooper MR. Hypothyroidism associated with aminoglutethimide in patients with prostate cancer. Arch Intern Med. 1994 May 9; 154 (9):1023-5
    View PubMed
  442. Thibault A, Cooper MR, Figg WD, Venzon DJ, Sartor AO, Tompkins AC, Weinberger MS, Headlee DJ, McCall NA, Samid D. A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. Cancer Res. 1994 Apr 1; 54 (7):1690-4
    View PubMed
  443. Sartor O, Cooper MR, Khleif SN, Myers CE. Suramin decreases circulating levels of insulin-like growth factor-I. Am J Med. 1994 Apr; 96 (4):390
    View PubMed
  444. Sartor O, Cooper M, Weinberger M, Headlee D, Thibault A, Tompkins A, Steinberg S, Figg WD, Linehan WM, Myers CE. Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer. J Natl Cancer Inst. 1994 Feb 2; 86 (3):222-7
    View PubMed
  445. Worland PJ, Kaur G, Stetler-Stevenson M, Sebers S, Sartor O, Sausville EA. Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Correlation with decreased H1 kinase activity. Biochem Pharmacol. 1993 Nov 17; 46 (10):1831-40
    View PubMed
  446. Thibault A, Figg WD, Cooper MR, Prindiville SA, Sartor AO, Headlee DJ, Myers CE. Anaphylactoid reaction with suramin. Pharmacotherapy. 1993 Nov-Dec; 13 (6):656-7
    View PubMed
  447. Sartor O, Robbins KC. Substrate specificity for normal but not mutationally activated variants of src family kinases. J Biol Chem. 1993 Oct 5; 268 (28):21014-20
    View PubMed
  448. Myers C, Trepel J, Sartor O, Cooper M, Ranson M, Toko T, Linehan MW. Antigrowth factor strategies. Cancer. 1993 Feb 1; 71 (3 Suppl):1172-8
    View PubMed
  449. Schlaifer D, Cooper MR, Attal M, Sartor AO, Trepel JB, Laurent G, Myers CE. Myeloperoxidase: an enzyme involved in intrinsic vincristine resistance in human myeloblastic leukemia. Blood. 1993 Jan 15; 81 (2):482-9
    View PubMed
  450. Sartor O, McLellan CA, Myers CE, Borner MM. Suramin rapidly alters cellular tyrosine phosphorylation in prostate cancer cell lines. J Clin Invest. 1992 Dec; 90 (6):2166-74
    View PubMed
  451. Sartor O, McLellan CA, Chiueh T. Comparison of src-family cDNAs reveals distinct mechanisms underlying focus formation in transfected fibroblasts. J Biol Chem. 1992 Oct 15; 267 (29):21044-51
    View PubMed
  452. Cardinali M, Sartor O, Robbins KC. Suramin, an experimental chemotherapeutic drug, activates the receptor for epidermal growth factor and promotes growth of certain malignant cells. J Clin Invest. 1992 Apr; 89 (4):1242-7
    View PubMed
  453. Sartor O, Moriuchi R, Sameshima JH, Severino M, Gutkind JS, Robbins KC. Diverse biologic properties imparted by the c-fgr proto-oncogene. J Biol Chem. 1992 Feb 15; 267 (5):3460-5
    View PubMed
  454. Grem JL, McAtee N, Murphy RF, Balis FM, Steinberg SM, Hamilton JM, Sorensen JM, Sartor O, Kramer BS, Goldstein LJ. A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma. J Clin Oncol. 1991 Oct; 9 (10):1811-20
    View PubMed
  455. Sartor O, Sameshima JH, Robbins KC. Differential association of cellular proteins with family protein-tyrosine kinases. J Biol Chem. 1991 Apr 5; 266 (10):6462-6
    View PubMed
  456. Bowers CY, Sartor AO, Reynolds GA, Badger TM. On the actions of the growth hormone-releasing hexapeptide, GHRP. Endocrinology. 1991 Apr; 128 (4):2027-35
    View PubMed
  457. Sartor O, Gregory FS, Templeton NS, Pawar S, Perlmutter RM, Rosen N. Selective expression of alternative lck mRNAs in human malignant cell lines. Mol Cell Biol. 1989 Jul; 9 (7):2983-8
    View PubMed
  458. Rosen N, Sartor O, Foss F, Bolen JB. Altered expression of src-related tyrosine kinases in human colon cancer Cold Spring Harbor Symposia (Cancer Cells). 1989; 161-166.
  459. Foss FM, Veillette A, Sartor O, Rosen N, Bolen JB. Alterations in the expression of pp60c-src and p56lck associated with butyrate-induced differentiation of human colon carcinoma cells. Oncogene Res. 1989; 5 (1):13-23
    View PubMed
  460. Lebacq-Verheyden AM, Krystal G, Sartor O, Way J, Battey JF. The rat prepro gastrin releasing peptide gene is transcribed from two initiation sites in the brain. Mol Endocrinol. 1988 Jun; 2 (6):556-63
    View PubMed
  461. Battey JF, Lebacq-Verheyden AM, Krystal G, Markowitz S, Sartor O, Way J. Regulation of the expression of the human preprogastrin-releasing peptide gene and post-translational processing of its gene product. Ann N Y Acad Sci. 1988; 547:30-40
    View PubMed
  462. Sartor O, Anday E. Campylobacter jejuni enteritis in a premature neonate. South Med J. 1987 Dec; 80 (12):1593-4
    View PubMed
  463. Sartor O, Sander GE. Unusual variant of eosinophilic fasciitis. South Med J. 1985 Nov; 78 (11):1387-9
    View PubMed
  464. Sartor O, Bowers CY, Reynolds GA, Momany FA. Variables determining the growth hormone response of His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 in the rat. Endocrinology. 1985 Oct; 117 (4):1441-7
    View PubMed
  465. Sartor O, Bowers CY, Chang D. Parallel studies of His-DTrp-Ala-Trp-DPhe-Lys-NH2 and human pancreatic growth hormone-releasing factor-44-NH2 in rat primary pituitary cell monolayer culture. Endocrinology. 1985 Mar; 116 (3):952-7
    View PubMed
  466. Sartor AO, Bowers CY. Hypothalamic hypophysiotropic hormones: Generalizations, concepts, and mechanisms. Rational Drug Therapy. 1983; 17(7):1-6.
  467. Spirtes MA, Woods KS, Sartor AO, Gerber AR, Wheeler WF. The in vitro effects of L-Prolyl L-Leucyl glycinamide (MIF-I) on the guanylate cyclase system of a rat brain mitochondrial fraction. Neuropeptides. 1981; (1):391-400.
  468. Spirtes MA, Gerber AR, Wood KS, Sartor AO, Christensen CW. The effects of Mif-I on in vitro c-GMP production by a particulate rat brain fraction. Neuropharmacology. 1980 Jul; 19 (7):687-9
    View PubMed
PST-20548416